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     1. INTRODUCTION 
  Anxiety is an emotion characterized by an unpleasant state of inner turmoil, often 
accompanied by nervous behavior, such as pacing back and forth, somatic complaints, and 
rumination1. It is the subjectively unpleasant feelings of dread over anticipated events, such as 
the feeling of imminent death.2 Anxiety is not the same as fear, which is a response to a real or 
perceived immediate threat, whereas anxiety is the expectation of future threat. 3 Anxiety is a 
feeling of uneasiness and worry, usually generalized and unfocused as an overreaction to a 
situation that is only subjectively seen as menacing.4 It is often accompanied by muscular 
tension, restlessness, fatigue and problems in concentration. Anxiety can be appropriate, but 
when experienced regularly the individual may suffer from an anxiety disorder. 
  They are a group of mental illnesses, and the distress they cause can keep you from 
carrying on with your life normally. For people who have one, worry and fear are constant and 
overwhelming, and can be disabling. But with treatment, many people can manage those feelings 
and get back to a fulfilling life5. 
  Anxiety can be either a short term "state" or a long term "trait". Whereas trait anxiety 
represents worrying about future events, anxiety disorders are a group of mental disorders 
characterized by feelings of anxiety and fear. Anxiety disorders are partly genetic but may also be 
due to drug use, including alcohol, caffeine, and benzodiazepines (which are often prescribed to 
treat anxiety), as well as withdrawal from drugs of abuse. They often occur with other mental 
disorders, particularly bipolar disorder, eating disorders, major depressive disorder, or certain 
personality disorders. Common treatment options include lifestyle changes, medication, and 
therapy. 
1.1 TYPES OF ANXIETY DISORDERS 6 
  Anxiety disorders are classified according to the severity and duration of their 
symptoms and specific behavioral characteristics. Types of anxiety disorders include: 
1. Generalized anxiety disorder (GAD) 
2. Panic disorder 
3. Phobias 
4. Obsessive-compulsive disorder (OCD) 
5. Post-traumatic stress disorder (PTSD) 
6. Separation anxiety disorder (which is almost always seen in children) 
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1.1.1 GENERALIZED ANXIETY DISORDER 
  Generalized anxiety disorder (GAD) is the most common anxiety disorder. It affects 
about 5% of Americans over the course of their lifetimes.  
It is characterized by: 
 A more-or-less constant state of worry and anxiety, which is out of proportion to the 
level of actual stress or threat in one's life. 
 The anxiety occurs on most days during a period of more than 6 months despite the lack 
of an obvious or specific stressor. (It worsens with stress, however.) 
 Patients with GAD may experience physical symptoms (such as gastrointestinal 
complaints) in addition to, or even in place of, mental worries. 
 People with GAD tend to be unsure of themselves, overly perfectionist, and 
conforming. 
  Given these conditions, a diagnosis of GAD is confirmed if three or more of the 
following symptoms are present (only one for children) on most days for 6 months: 
 Being on edge or very restless 
 Feeling tired 
 Having difficulty with concentration 
 Being irritable 
 Having muscle tension 
 Experiencing disturbed sleep 
  Symptoms can cause significant distress and impair normal functioning. To be 
classified as GAD, they should not be due to a medical condition, another mood disorder, or 
psychosis. GAD rarely occurs by itself. It typically occurs along with another type of anxiety 
disorder, depression, or substance abuse. 
1.1.2 PANIC DISORDER 
  Panic disorder is characterized by periodic attacks of anxiety or terror (panic attacks). 
Panic attacks usually last 15 - 30 minutes, although residual effects can persist much longer. 
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Panic attacks can occur in nearly every anxiety disorder, not just panic disorder. In other anxiety 
disorders, however, there is always a cue or specific trigger for the attack. A diagnosis of panic 
disorder is made under the following conditions: 
 A person experiences at least two recurrent, unexpected panic attacks. 
 For at least a month following the attacks, the person fears that another will occur. 
Symptoms:  
  During a panic attack a person feels intense fear or discomfort and experiences at least 
four or more of the following symptoms: 
 Rapid heart beat 
 Sweating 
 Shakiness 
 Shortness of breath 
 A choking feeling or a feeling of being smothered 
 Dizziness 
 Nausea 
 Feelings of unreality 
 Numbness 
 Either hot flashes or chills 
 Chest pain 
 A fear of dying 
 A fear of going insane 
  Women may be more likely than men to experience shortness of breath, nausea, and 
feelings of being smothered. Men may be more likely than women to have sweating and 
abdominal pain. Panic attacks that include only one or two symptoms, such as dizziness and heart 
pounding, are known as limited-symptom attacks. These may be either residual symptoms after a 
major panic attack or precursors to full-blown attacks. 
1.1.3 PHOBIC DISORDERS 
  Phobias, manifested by overwhelming and irrational fears, are common. In most cases, 
people can avoid or at least endure phobic situations, but in some cases, as with agoraphobia, the 
anxiety associated with the feared object or situation can be incapacitating. 
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AGORAPHOBIA: 
  Agoraphobia is described as fear of being in public places or open areas. (The term 
comes from the Greek word agora, meaning outdoor marketplace.) In its severest form, 
agoraphobia is characterized by a paralyzing terror of being in places or situations from which 
the patient feels there is neither escape nor accessible help in case of an attack. Consequently, 
people with agoraphobia confine themselves to places in which they feel safe, usually at home. 
The patient with agoraphobia often makes complicated plans in order to avoid confronting feared 
situations and places. 
SOCIAL PHOBIA: 
  Social phobia, also known as social anxiety disorder, is the fear of being publicly 
scrutinized and humiliated and is manifested by extreme shyness and discomfort in social 
settings. This phobia often leads people to avoid social situations and is not due to a physical or 
mental problem (such as stuttering, acne, or personality disorders). 
  The associated symptoms vary in intensity, ranging from mild and tolerable anxiety to a 
full-blown panic attack. (Unlike a panic attack, however, social phobia is always directly related 
to a social situation.) Symptoms include sweating, shortness of breath, pounding heart, dry 
mouth, and tremor. 
SPECIFIC PHOBIAS: 
  Specific phobias (formerly simple phobias) are an irrational fear of specific objects or 
situations. Specific phobias are very common. Most cases are mild and not significant enough to 
require treatment. 
  The most common specific phobias are fear of animals (usually spiders, snakes, or 
mice), flying (pterygophobia), heights (acrophobia), water, injections, public transportation, 
confined spaces (claustrophobia), dentists (odontiatophobia), storms, tunnels, and bridges. 
  When confronting the object or situation, the phobic person experiences panicky 
feelings, sweating, avoidance behavior, difficulty breathing, and a rapid heartbeat. Most phobic 
adults are aware of the irrationality of their fear, and many endure intense anxiety rather than 
disclose their disorder. 
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1.1.4 OBSESSIVE-COMPULSIVE DISORDER 
  Obsessive-compulsive disorder (OCD) is a condition marked by unwanted intrusive and 
repeated thoughts (obsessions) and behaviors (compulsions): 
  Obsessions are recurrent or persistent mental images, thoughts, or ideas. The obsessive 
thoughts or images can range from mundane worries about whether one has locked a door to 
bizarre and frightening fantasies of behaving violently toward a loved one. 
  Compulsive behaviors are repetitive, rigid, and self-directed routines that are intended 
to prevent the manifestation of an associated obsession. Such compulsive acts might include 
repetitive checking for locked doors or unlit stove burners or calls to loved ones at frequent 
intervals to be sure they are safe. Some people are compelled to wash their hands every few 
minutes or to spend inordinate amounts of time cleaning their surroundings in order to subdue the 
fear of contagion. 
  A critical feature in this disorder is an inflated sense of responsibility, in which the 
patient's thoughts center on possible dangers and an urgent need to do something about them.  
  Over half of patients with OCD have obsessive thoughts without the ritualistic 
compulsive behavior. Although they recognize that the obsessive thoughts and ritualized 
behavior patterns are senseless and excessive, they cannot stop them. OCD often accompanies 
depression or other anxiety disorders. Some patients find that their symptoms subside over time, 
while others experience a worsening of symptoms. 
  Symptoms in children may be mistaken for behavioral problems (taking too long to do 
homework because of perfectionism, refusing to perform a chore because of fear of germs). 
Children do not usually recognize that their obsessions or compulsions are excessive. 
1.1.5 POST-TRAUMATIC STRESS DISORDER 
  Post-traumatic stress disorder (PTSD) is a severe, persistent emotional reaction to a 
traumatic event that severely impairs one’s life. It is classified as an anxiety disorder because of 
its symptoms. Not every traumatic event leads to PTSD, however. There are two criteria that 
must be present to qualify for a diagnosis of PTSD 
  The patient must have directly experienced, witnessed, or learned of a life-threatening 
or seriously injurious event. 
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  The patient's response is intense fear, helplessness, or horror. Children may behave with 
agitation or with disorganized behavior. 
TRIGGERING EVENTS: 
  PTSD is triggered by violent or traumatic events that are usually outside the normal 
range of human experience. War is a prime example. There is some evidence that events most 
likely to trigger PTSD are those that involve deliberate and destructive behavior (such as murder 
or rape) and those that are prolonged or physically challenging. Such events include, but are not 
limited to, experiencing or witnessing sexual assaults, accidents, military combat, natural 
disasters (such as earthquakes), or unexpected deaths of loved ones. PTSD may also occur in 
people who have serious illness and receive aggressive treatments or who have close family 
members or friends with such conditions. 
SYMPTOMS: 
  There are three basic sets of symptoms associated with PTSD. They may begin 
immediately after the event or can develop up to a year afterward: 
1.Re-experiencing. In such cases, patients persistently re-experience the trauma in at least one of 
the following ways: in recurrent images, thoughts, flashbacks, dreams, or feelings of distress at 
situations that remind them of the traumatic event. Children may engage in play, in which 
traumatic events are enacted repeatedly. 
2.Avoidance. Patients may avoid reminders of the event, such as thoughts, people, or any other 
factors that trigger recollection. They tend to have an emotional numbness, a sense of being in a 
daze or of losing contact with their own identity or even external reality. They may be unable to 
remember important aspects of the event. 
3.Increased Arousal. This includes symptoms of anxiety or heightened awareness of danger 
(sleeplessness, irritability, being easily startled, or becoming overly vigilant to unknown 
dangers). 
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1.1.6 SEPARATION ANXIETY DISORDER 
  Separation anxiety disorder almost always occurs in children. It is suspected in children 
who are excessively anxious about separation from important family members or from home. For 
a diagnosis of separation anxiety disorder, the child should also exhibit at least three of the 
following symptoms for at least 4 weeks: 
 Extreme distress from either anticipating or actually being away from home or being 
separated from a parent or other loved one 
 Extreme worry about losing or about possible harm befalling a loved one 
 Intense worry about getting lost, being kidnapped, or otherwise separated from loved 
ones 
 Frequent refusal to go to school or to sleep away from home 
 Physical symptoms such as headache, stomach ache, or even vomiting, when faced with 
separation from loved ones 
  Separation anxiety often disappears as the child grows older, but if not addressed, it 
may lead to panic disorder, agoraphobia, or combinations of anxiety disorders. 
  The cause of anxiety disorders is a combination of genetic and environmental factors.7 
Risk factors include a history of child abuse, family history of mental disorders, and poverty. To 
be diagnosed symptoms typically need to be present at least six months, be more than would be 
expected for the situation, and decrease functioning. Without treatment, anxiety disorders tend to 
remain.6 
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1.2 RISK FACTORS 
  Risk factors for anxiety disorders depend in part on the specific disorder. General risk 
factors include: 
1. Gender: With the exception of obsessive-compulsive disorder (OCD), women have 
twice the risk for most anxiety disorders as men. 
2. Age: Phobias, OCD, and separation anxiety typically show up early in childhood, while 
social phobia and panic disorder often develop during the teen years. 
3. Traumatic Events:  Traumatic events can trigger anxiety disorders, particularly post-
traumatic stress disorder. 
4. Medical Conditions: Although causal relationships have not been established, certain 
medical conditions have been associated with increased risk of panic disorder. They 
include migraines, obstructive sleep apnea, mitral valve prolapse, irritable bowel 
syndrome, chronic fatigue syndrome, and premenstrual syndrome. 
1.3 SIGNS AND SYMPTOMS 7 
 Excessive worry 
 Sleep problems 
 Irrational fears 
 Muscle tension 
 Chronic indigestion 
 Stage fright 
 Self-consciousness 
 Panic 
 Flashbacks 
 Perfectionism 
 Compulsive behaviors 
 Self-doubt 
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1.4 PATHOPHYSIOLOGY & NEUROTRANSMITTERS INVOLVED IN ANXIETY: 
1.4.1 GAMMA-AMINO BUTYRIC ACID: 
   There are different inhibitory neurotransmitters in the CNS; most of the abundant and 
important is Gamma-amino butyric acid (GABA). The role of the inhibitory neurotransmitter 
GABA has long been regarded as Centre for the regulation of anxiety and this neurotransmitter 
system is the main target of benzodiazepines and other anxiety related drugs used to treat anxiety 
disorders. 8 
The excitability states in all brain areas are mainly controlled by GABA and the ongoing level of 
neuronal activity is regulated by the equilibrium between excitatory inputs (mostly 
glutamatergic) and inhibitory GABAergic activity. If the balance swings towards GABA, then 
sedation, amnesia and ataxia appear. On the other hand, the mildest attenuation of the 
GABAergic system results in restlessness, insomnia, arousal, anxiety and exaggerated 
reactivity. 9 
  Historically, the GABA system has been thought to play a role in anxiety disorders 
largely because of the effectiveness of the benzodiazepines, which are well known to act 
primarily on GABA receptors, in the management of anxiety. 10 
When there is binding of GABA with the GABA-A±benzodiazepine receptor complex, it acts as 
an agonist: inducing conformational changes, with which the permeability of the central pore to 
chloride ions gets increased. The resulting chloride flux hyperpolarizes the neuron, leads to 
reduction in its excitability and producing a general inhibitory effect on neuronal activity.  
  The anxiolytic effects of drugs that act on the GABA receptor provide some of the 
strongest evidence that GABA dysfunction underlies anxiety states. Agents such as the 
benzodiazepines, gabapentin, pregabalin, valproate, vigabatrin, tiagabine demonstrate clinically 
relevant anxiolytic effects. 11 
1.4.2 BENZODIAZEPINES:  
  Benzodiazepines have been widely used to manage anxiety disorders, from the short-
term relief of anxiety symptoms to specific anxiety syndromes (i.e. GAD, phobia, 
PD).12 Benzodiazepines augment the GABAergic inhibition via GABA-A 
receptors. 13 Benzodiazepine binding allosterically changes the receptor complex to increase the 
GABA efficiency, which enables the GABAergic circuits to produce a larger inhibitory effect.  
  There is established efficacy of Benzodiazepines in the treatment of GAD, for which a 
drug such as Diazepam is suitable. 14 Typical side effects of BZD include drowsiness and 
impairment of cognitive and motor function. 15 
Study Of Anxiolytic Activity In Mice Using Vacha Churanam (Rasayana Preparation- Ayurvedic System Of Medicine) 
 
Department of Pharmacology Page 10 
 
Benzodiazepines can potentiate the sedative effects of alcohol and other centrally acting drugs. 
Respiratory depression has been reported in some patients receiving benzodiazepines with 
clozapine. Drug discontinuation, even with a slow taper, can cause troublesome withdrawal 
reactions and rebound anxiety, which may necessitate re starting treatment. 16 
1.4.3 GABAPENTIN:  
  Gabapentin was designed as a GABA analog that could penetrate the blood- brain 
barrier. Although the anxiolytic properties of gabapentin are likely to be linked to its effects on 
the GABA system, gabapentin has a high affinity for the α2δ subunit of presynaptic P/Q-type, 
voltage–sensitive Ca2+channels modulates certain types of Ca2+ current, and the release of several 
monoamine neurotransmitters gets reduced 17 
In Pre-clinical studies, gabapentin demonstrated anxiolytic effects similar to that of the 
BZDs. 18 Gabapentin has shown to effectively ameliorate the symptoms of PD and social phobia 
in placebo-controlled clinical studies. The most commonly reported adverse effects in 
gabapentin-treated patients with these anxiety disorders are dizziness, dry mouth, headache, 
nausea and somnolence. 19 
  Case reports have suggested the potential use of gabapentin in the management of 
symptoms of PTSD 20, GAD, refractory PD 21 and GAD and schizophrenia/ mood disorders with 
comorbid PD and OCD. The most common side effects noted in these reports were drowsiness 
and dizziness. 22Abrupt discontinuation of augmentative gabapentin treatment has been found to 
lead to withdrawal symptoms such as rebound anxiety related symptoms of depression and sleep 
disturbances. 23  
1.4.4 PREGABALIN:  
  Pregabalin is another GABA analog with similarities to gabapentin 24; it is functionally 
similar to gabapentin. Pregabalin is thought to act by increasing total GABA content in the brain 
via an undetermined mechanism. 25 
Pregabalin was found to induce anxiolytic-like effects in a dose dependent manner in a 
preclinical murine model of anxiety 26 and reduces the GAD symptoms and social phobia in 
randomized, placebo-controlled clinical trials.27 the most commonly reports adverse events in 
pregabalin clinical trials were dizziness, somnolence, dry mouth, nausea and ataxia. 
1.4.5 GLUTAMATE:  
  The excitatory action of amino acid L-glutamate in the mammalian brain and spinal 
cord has been known since the 1950s. 28 Glutamate is the main excitatory neurotransmitter in the 
human Central Nervous System (CNS). Glutamate is ubiquitous within the central nervous 
system and has been shown to play important roles in different brain functions, including 
Study Of Anxiolytic Activity In Mice Using Vacha Churanam (Rasayana Preparation- Ayurvedic System Of Medicine) 
 
Department of Pharmacology Page 11 
 
neurodevelopment (e.g., differentiation, migration and survival), 29 learning (e.g., long-term 
potentiation and depression), 30 acute neurodegeneration (e.g., cerebral ischemia, traumatic brain 
injury) 31 chronic neurodegeneration (e.g., Huntington’s disease, Alzheimer’s disease) 32 and, 
more recently, the stress response and anxiety disorders. 33 
  Glutamate controls the synaptic release by a wide range of presynaptic receptors. These 
include not only the Group II and Group III glutamate metabotropic receptors but also 
cholinergic (nicotinic and muscarinic) receptors, adenosine (A1), kappa opioid, γ-amino butyric 
acid (GABA B), cholecystokinin and neuropeptide Y (Y2) receptors. 34 
  Glutamate mainly show its actions through ligand-gated ion channel (ionotropic) 
receptors, including the N- methyl-d-aspartate (NMDA), kainate, and -amino- 3-hydroxy-5-
methyl-4-isoxazole propionic acid (AMPA) subtypes, and G protein-coupled metabo- tropic 
receptors (mGluR1-8). 35 Each NMDAR complex consists of four (occasionally five) subunits: 
two NR1 subunits (generated by alternative splicing of a single gene, NR1), and two or three 
NR2 subunits (coded by four related genes, NR2 A–D). 
   
 
   Fig. 1: Different neurotransmitters involved in anxiety 
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  Recently, a third type of NMDA receptor subunit (NR3), which dramatically reduces 
ion permeability, has been described. 36This situation leads to an enormous heterogeneity in 
terms of modulation of neurochemical profiles. 37 
  Recently, a third type of NMDA receptor subunit (NR3), which dramatically reduces 
ion permeability, has been described. 36This situation leads to an enormous heterogeneity in 
terms of modulation of neurochemical profiles. 37 
A major role is played by Glutamatergic system in the pathogenesis of anxiety and fear 
conditioning. Many studies suggest that glutamatergic neurotransmission of limbic system plays 
a pivotal role in the pathogenesis of anxiety disorders. 38Severe stress exposure directly leads to 
glutamate excitotoxicity, which can cause neuronal damage and/or death. By decreasing the level 
of endogenously released glutamate, the anxiolysis could be induced. NMDA receptor would be 
activated by diminished glutamate release but to less extent and CNS excitation would remain at 
a stable stage. Such an effect can be achieved by switching on the regulatory machinery of 
presynaptic glutamate release. 39 
  Monosodium glutamate (MSG) [C5H8NO4NaH2O] a sodium salt of naturally occurring 
(non-essential) L- form of glutamic acid, is one of the flavor enhancers, which is mainly used as 
an ingredient in various food products. 40 Glutamate Consumption has been linked to obesity and 
metabolic syndrome independent of physical activity and calorie intake. 41 Some researchers 
have also reported neurotoxic effects of glutamate. 42 
  MSG is an excitotoxic which excites the neurons and may cause their death. Moreover, 
it has been reported that MSG is a neurotoxic substance, which is capable of producing 
degeneration of population of neurons, accompanied by pathological conditions, such as stroke, 
epilepsy, schizophrenia, anxiety, depression, Parkinson’s disease, Alzheimer’s disease, 
Huntington’s disease, and amyotrophic lateral sclerosis. 43This could be due to its well 
knownexcitotoxic effect, as MSG can cause overexcitotoxicity of neuronal cells to damage or 
death point, resulting in brain injury, mostly accompanied by oxidative stress. 44Spermidine, 
spermine and putrescine, which are polyamines, are found in green vegetables, milk products, 
and meat. Polyamines are naturally occurring, ubiquitous, low molecular weight aliphatic 
polycations with nucleophilic centers, which are found at elevated levels in the brain.45 
  The polyamines are a group of aliphatic amines with a polycationic structure, carrying a 
positive charge on each nitrogen atom at physiological pH. 46Polyamines can interact with 
several intracellular targets, including nucleic acids and enzymes, and exert several selective and 
complex actions on a variety of ion channels. 47Among them, especially remarkable is the dual 
modulation of a-amino-3-hydroxy- 5-methyl-4-isoxazole propionate (AMPA) 48 and N-methyl-
Study Of Anxiolytic Activity In Mice Using Vacha Churanam (Rasayana Preparation- Ayurvedic System Of Medicine) 
 
Department of Pharmacology Page 13 
 
D-aspartate (NMDA) receptors 49, which have been implicated in important plasticity events, 
such as learning and memory. 50 
  Polyamines (125–250 nmol, i.c.v.) cause damage of hippocampus and learning 
impairment in rats at high doses 51 and also increase dizocilpine-induced impairment of a 
learning task in rats. 52 These studies show that high cerebral levels of polyamines are neurotoxic 
and impair learning and memory. 53 
  Different studies suggest that antidepressant drugs (SSRIs, SNRIs, TCAs, and MAOIs) 
decreases glutamatergic activity in some regions (like hippocampus) on chronic 
administration 54 and that NMDA receptor antagonists on acute administration have antianxiety 
and antidepressant properties in preclinical and clinical models. 55 Glutamate release is inhibited 
by Lamotrigine and is currently used as an anticonvulsant as well as a treatment for bipolar 
depression. A clinical study has shown lamotrigine to be effective in certain PTSD symptoms 
(re-experiencing and avoidance/ numbing). 56 Similarly, topiramate, an AMPA/ kainate blocker 
among other actions, was found in an open-label study to reduce re-experiencing symptoms in 
PTSD. 57 
1.4.6 SEROTONIN: 
   5-HT plays a vital role in the development and the persistence of anxiety disorders in 
addition to GABA. Different studies have shown that 5-HT concentration when increased in the 
brain also increases anxiety and a reduction of 5-HT level reduces anxiety. 58 Serotonergic 
neurons are involved in the alteration of appetite, energy, sleep, mood and cognitive function in 
anxiety. Its role in anxiety is supported by its modulating effect on the locus coeruleus and its 
projections to the amygdale. Fear and stress activate serotonergic pathways. 59  
  Several studies show that anxiety disorders patients may have genetic polymorphisms 
in the 5-HT transporter 60 or in the 5-HT2A receptor 61 and the 5-HT1A receptor. 62 Panic 
disorder patients show reduction in the number of 5-HT1A receptors in the limbic 
system 63 There is an involvement of 5-HT3 receptors in the regulation of anxiety 64 but clinical 
efficacy is still uncertain.65 
  SNRIs (Serotonin-Norepinephrine reuptake inhibitors) results in 5-HT and NA 
transporters binding to selectively inhibit the reuptake of these neurotransmitters from the 
synaptic clefts. SNRIs show “dual mode of action”. SNRIs block the reuptake of both 5-HT and 
NA with differing selectivity. Whereas milnacipran blocks reuptake of 5- HT and NA with equal 
affinity, duloxetine has a 10-fold greater selectivity for 5- HT, and venlafaxine show 30-fold 
greater selectivity for 5-H. 66 
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  Venlafaxine was the first SNRI that comes in market. Venlafaxine inhibits neuronal 
uptake of 5- HT (most potent, present at low doses), NA (moderate potency, present at high 
doses) and dopamine (DA) in order of decreasing potency. Venlafaxine has no affinity for α2- or 
β- adrenoceptors, benzodiazepine or opiate receptors. It has a much greater affinity for the 5- HT 
transporter than for the norepinephrine (NE) transporter. At low doses, it inhibits the 5- HT 
transporter almost exclusively, acting like a selective serotonin reuptake inhibitor (SSRI), with 
significant NE reuptake inhibition only occurring at higher doses. 67 
1.4.7 CHOLECYSTOKINNIN: 
   CCK, a neuropeptide, was, like 5-HT, discovered originally in the digestive tract and 
found in the CNS later. 68 CCK‐immunoreactive fibers and CCK (2) receptors are most 
abundantly present in anatomical locations like periaqueductal gray (PAG), which mediate 
anxiety.69 The CCK2 receptor regulates the fear-related behaviours in humans and 
animals 70 CCK-4 injection triggers the panic attacks in patients with a history of panic 
disorder. 71 
1.4.8 ADENOSINE: 
  Adenosine results due to hydrolysis of 5‐adenosine monophosphate and is transformed 
to inosine, which is then stored as adenosine triphosphate. 72 Adenosine is also involved in the 
regulation of anxiety-related behavior. High doses of caffeine, which is the nonselective 
adenosine receptor antagonist, induce fear in healthy people and trigger panic attacks in anxiety 
disorder patients. 73 Adenosine through A1 and A2A receptors exert anxiolytic effect through its 
facilitatory influence on release of GABA in the septum and hippocampus.74 On treatment with 
caffeine, rats were more anxious in the elevated plus-maze test (X-maze) 75 and a free exploratory 
paradigm, 76 while an adenosine-1 receptor agonist had an anxiolytic effect in the X-maze. 77 
1.4.9 ACETYLCHOLINE:  
  Acetylcholine plays a pivotal role in learning and memory processes. Acetylcholine 
levels can be modulated by stress in several brain regions. Acetylcholinesterase present in the 
CNS catalyzes the hydrolysis of acetylcholine to choline. 78 Acetylcholine is released in the 
synaptic cleft where it activates both presynaptic and postsynaptic cholinergic receptors namely 
nicotine and muscarinic leading to an increase of cholinergic transmission which results in 
cognitive impairment. 79 Cholinergic input to hippocampus is enhancing in response to 
anxiogenic and stressful stimuli.80 Muscarinic M1 receptors induce anxiety through 
noradrenergic pathway. Nicotine facilitates GABAergic neuron that induces anxiety. 81 
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1.4.10 CANNABINOIDS: 
   Cannabinoid receptor is widely distributed in the CNS present in the brain areas related 
to stress responses such as the central amygdala and the paraventricular nucleus of the 
hypothalamus and in the limbic system. Cannabinoid-1 agonist can induce both anxiolytic and 
anxiogenic responses in animal studies.  Low doses of the cannabinoid produce anxiolytic 
effects, whereas higher doses result in anxiety. Acute administration of the selective CB1 
receptor antagonist SR141716A induced anxiety-like responses in the elevated plus maze and the 
defensive withdrawal tests. CB1 knockout mice showed anxiogenic-like response in the 
light/dark box. 82 
1.4.11 CORTICOTROPHIN-RELEASING FACTOR:  
  Corticotrophin-Releasing Factor is made up of peptide containing 41 amino acids. This 
neurotransmitter in CNS acts as a key mediator of autonomic, immune, behavioral and endocrine 
stress responses. The peptide appears to be anxiogenic, proinflammatory and leads to increase 
pain perception. 83 Corticotrophin-Releasing Factor is an essential component, which mediates 
endocrine and behavioral anxiety-like responses, and stimulation of CRF2 may produce 
anxiolytic-like effects. 84 
1.4.12 MELATONIN: 
   Melatonin is synthesized by the pineal gland during night and acts through G-protein 
coupled receptors (GPCRs), MT1 (MEL1a) and MT2(MEL1b). Melatonin is involved in 
numerous physiologic processes including circadian rhythms, mood regulation, anxiety, sleep, 
appetite, immune responses and cardiac functions. Preoperative anxiolytic effects of melatonin 
found a significant reduction in anxiety. MT2 receptors modulate anxiety levels and consequently 
this receptor may become a novel target for the treatment of anxiety. 85 
1.4.13 SUBSTANCE P:  
  Substance P neurotransmission has been associated with aversion and anxiety 
behavioral model. Substance P act primarily at the neurokinnin-1 (NK1) receptor. NK-1 
antagonists are mediated by the dorsal raphe nucleus. NK-1 receptor exhibit anxiolytic effects in 
several models including elevated plus maze and social interaction tests. Disruption of NK-1 
receptor results in 5-HT1A-receptor desensitization and anxiolytic behavior and the effect of 
substance P play a role in anxiogenic behavior. 86 
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1.4.14 NEUROACTIVE STEROIDS (NAS): 
   GABA-A receptor is a direct binding site for the neuroactive steroids. Enzymes 
involved in the biosynthesis of these NASs, such as 5α- reductase and 3α-hydroxy-steroid 
oxidoreductase are found in key neuroanatomic structures involved in the anxiety such as the 
amygdala and the hippocampus. Positive modulation of the GABA-A receptor has been 
associated with anxiolytic activity whereas anxiogenic activity in animals models of anxiety in 
association with negative modulation. The potential role of NAS analogues is in the treatment of 
anxiety disorders.  
1.5 DIAGNOSIS OF ANXIETY87 
  Diagnosis is made using the Diagnostic and Statistical Manual of Mental Disorders IV 
(Text Revision) also called DSM-IV-TR. 
  The manual lays down criteria for diagnosis of each of the types of anxiety disorders. If 
these criteria are fulfilled for at least 6 months, the diagnosis may be made. Since anxiety 
disorders often coexist with other psychiatric disorders, diagnosis may be a challenge. For 
example, nearly 60% of patients with generalized anxiety disorders have accompanying panic 
disorder or depressive disorders. 
1.5.1 DSM IV-TR CRITERIA FOR GENERALIZED ANXIETY DISORDER 
  The DSM IV-TR Criteria for Generalized Anxiety Disorder include: 
 Presence of excessive anxiety about events or activities occurring on most days for at 
least 6 months 
 Losing control over the worry intensity 
 At least three of the symptoms including restless or jumpiness, fatigue, lack of 
concentration, irritability, muscle tension and sleep problems 
 Significant interference of symptoms with social and work related functioning or leading 
to significant distress 
 No other mood disorder or psychiatric problem 
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1.5.2 DSM IV-TR CRITERIA FOR PANIC DISORDER 
  The DSM IV-TR criteria for Panic Disorder include: 
  Frequent panic attacks without cause or warning. There may be presence of 
agoraphobia (fear of large open spaces). There are no other psychiatric or medial ailments that 
explain the attacks. 
 At least a single attack is followed by fear of: 
 Fear and concern regarding another attack 
 Worry regarding the consequences of an attack 
 Change in behavior with relation to the panic attacks 
1.5.3 DSM IV-TR CRITERIA FOR PTSD 
  The DSM IV-TR criteria for Post-traumatic stress Disorder include: 
  PTSD patients have a history of experiencing, witnessing or confronting an event that 
involved treat or actual risk of death or serious harm. The experience may be accompanied with 
feelings of fear, helplessness or horror. The feelings of distress persist for at least 1 month. 
On presentation the patient may re-live the event by: 
 Recurrent recollections of the event with thoughts, perception or flashes of images 
 Recurrent dreams 
 Sense of reliving the incident with illusions, hallucinations and flashbacks 
 Severe psychological distress on exposure to cues to the event and a physiological 
reaction to the cues 
Patient avoids or feels at least three of the following: 
 Thoughts, feelings and conversation associated with the event 
 Activities, places, or people associated with the event 
 Loss of recall of the event 
 Decreased interest in significant activities 
 Detachment or estrangement from others 
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There may be associated symptoms of anxiety like: 
 Sleep problems 
 Irritability and anger outbursts 
 Lack of concentration 
 Increased vigilance 
 Increased jumpiness or startle response 
 Interference with social and work functioning 
1.5.4 DSM IV-TR CRITERIA FOR OBSESSIVE COMPULSIVE DISORDER 
  The DSM IV-TR Criteria for Obsessive compulsive Disorder include : 
 Obsessions include recurrent and intrusive thoughts, impulses or ideas. There are usually 
no excessive worries about real-life problems. Patient has attempted to ignore or suppress 
such thoughts and recognizes that the obsessional thoughts are a product of his or her own 
mind. 
 Compulsions are repeated behaviors and mental actions that the patient is driven to follow 
according to self-set rigid rules. The compulsions ease the anxiety and reduce distress. 
These are not realistic and are clearly excessive. 
 The compulsions may be recognised as excessive and may take over 1 hour a day. 
1.5.5 DIAGNOSING CHILDREN WITH ANXIETY 
  Diagnosing children with an anxiety disorder is difficult. Anxiety in children may 
manifest as behavioral problems or as a disruptive or rebellious nature. 
1.5.6 EXCLUSION OF MEDICAL CONDITIONS 
Exclusion of medical conditions:  
 Heart disease – Since chest pain and shortness of breath are common symptoms, heart 
disease and heart attacks should be ruled out. Mitral valve prolapse is a disorder where 
the mitral valve that lies between two chambers of the heart does not close well. This 
leads to impaired blood flow from the heart and back flow into the left atrium.There may 
be symptoms like chest pain, difficulty breathing especially after exercise, fatigue, cough, 
palpitations etc. this needs to be ruled out. 
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 Asthma – Panic attacks may mask asthma attacks 
 Over active thyroid may lead to palpitations and needs to be ruled out. 
 Low blood sugar or hypoglycaemia manifests as sweating and palpitations. 
 Substance abuse and caffeine over dose may lead to anxiety and similar symptoms. 
1.6 ANXIETY DISORDER STATISTICS88 
  Anxiety is a life altering condition. It's one that can affect the way you think, the way 
you feel, and the way you live your life. Unfortunately, anxiety is also incredibly common, 
affecting millions of people in the United States and millions more around the world. 
  This article will explore some key anxiety statistics. But the most important statistic you 
need to know is this: according to the National Institute of Mental Health (NIMH), 86% of those 
with anxiety disorders either do not seek treatment, or use treatments that are inadequate for 
stopping anxiety. 
1.6.1 LIFETIME PREVALENCE 
  While year to year statistics are interesting, lifetime prevalence is the most important 
statistic in terms of the number of people that suffer from anxiety. 12 month prevalence statistics 
only show the number of those living with anxiety now, but your chances of developing anxiety 
at some point in your life are based on previous lifetime prevalence data. 
  The following is the likelihood of developing an anxiety disorder at some point in your 
life. Note that this is data on adults only. 
 Any Anxiety Disorder: 28.8% 
 Generalized Anxiety Disorder: 5.7% 
 Obsessive Compulsive Disorder: 1.6% 
 Panic Disorder: 4.7% 
 Post-Traumatic Stress Disorder: 6.8% 
 Social Phobia: 12.1% 
 Specific (Other) Phobia: 12.5% 
 
  Every individual country has its own statistics, but they are likely to be somewhere near 
these overall numbers. Most other countries do not diagnose anxiety the same way as they do in 
the United States, nor do they adhere to the same measurements. 
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  These numbers also do not necessarily represent the only factors at play for whether 
you will develop anxiety. Genetics plays a strong role, especially with panic disorder, so if your 
family members have panic attacks you'll increase your chances of getting it too.  
1.7 ANTI- ANXIETY 
  An anxiolytic (also antipanic or anti anxiety agent) 89 is the medication or other 
intervention that inhibits anxiety. This effect is in contrast to anxiogenic agents, which increase 
anxiety. Together these categories of psychoactive compounds or interventions may be referred 
to as anxiotropic compounds or agents. Some recreational drugs such as alcohol (also known 
formally as ethanol) induce anxiolysis initially; however, studies show that many of these drugs 
are anxiogenic. Anxiolytic medications have been used for the treatment of anxiety disorder and 
its related psychological and physical symptoms. Anxiolytics have been shown to be useful in the 
treatment of anxiety disorder. Light therapy and other interventions have also been found to have 
an anxiolytic effect. 90Beta-receptor blockers such as propranolol and oxprenolol, although not 
anxiolytics, can be used to combat the somatic symptoms of anxiety such as tachycardia and 
palpitations. 91 
  Anxiolytics are also known as minor tranquilizers.92The term is less common in modern 
texts and was originally derived from a dichotomy with major tranquilizers, also known as 
neuroleptics or antipsychotics. There are concerns that some GABAergics (pertaining to or 
affecting the neurotransmitter GABA), such as benzodiazepines and barbiturates, may have an 
anxiogenic effect if used over long periods of time. 93 
1.8 DRUG CLASSIFICATION:  
1. Barbiturates  
– Phenobarbital  
– Primidone  
2. Benzodiazepines   
– Alprazolam (Xanax) 
– Bromazepam (Lectopam, Lexotan) 
– Chlordiazepoxide (Librium) 
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– Clonazepam (Klonopin, Rivotril) 
– Clorazepate (Tranxene) 
– Diazepam (Valium) 
– Flurazepam (Dalmane) 
– Lorazepam (Ativan) 
– Oxazepam (Serax, Serapax) 
– Temazepam (Restoril) 
– Triazolam (Halcion) 
3. Carbamates 
– meprobamate 
– tybamate 
– lorbamate. 
4. Antihistamines  
– Chlorphenamine 
– Diphenhydramine 
5. Opioids 
– buprenorphine 
6. Antidepressants 
– Mirtazapine 
– imipramine 
– amitriptyline 
– nortriptyline 
– desipramine 
7.  Sympatholytics 
– Beta blockers 
– Alpha blockers 
– Alpha-adrenergic agonist 
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8.Miscellaneous 
– Mebicar 
– Fabomotizole 
– Selank 
– Bromantane 
– Emoxypine 
– Azapirones 
– Pregabalin 
– Menthylisovalerate 
– Propofol 
– Racetams 
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1.9 MECHANISM OF ACTION OF ANXIOLYTICS94 
  Drugs to reduce anxiety have been used by human beings for thousands of years. One 
of the first anxiolytics and one that continues to be used by humans is ethanol. A detailed 
description of ethanol’s action may be found in Chapter 100. A number of other drugs including 
the barbiturates and the carbamates (meprobamate) were used in the first half of the 20th century 
and some continue to be used today.   This chapter focuses on current drugs that are used 
for the treatment of anxiety and approaches that are currently under investigation 
 CORTICOTROPIN-RELEASING FACTOR (CRF 
 GABAA RECEPTOR MODULATORS (BENZODIAZEPINES AND RELATED 
DRUGS) 
 SEROTONIN RECEPTOR MODULATORS AND 
 REUPTAKE INHIBITORS 
 NEUROKININ RECEPTOR ANTAGONISTS 
 GLUTAMATE RECEPTOR AGONISTS AND MODULATORS 
1.9.1 GABAA RECEPTOR MODULATORS (Benzodiazepines and related drugs) 
  A majority of the synapses in the mammalian CNS use the amino acids l-glutamic acid, 
glycine, or -aminobutyric acid (GABA) for signaling. GABA is formed by the decarboxylation of 
l-glutamate, stored in neurons, and released, and its action is terminated by reuptake; GABA’s 
action mimics the naturally occurring inhibitory transmission in the mammalian nervous system. 
Because of these findings, it has been accepted for over 20 years that GABA fulfills the 
characteristics of a neuro transmitter. Along with l-glutamate, acetylcholine, and serotonin, 
GABA possesses two different types of receptor conserved across different species and phyla 
that control both excitation and inhibition.  
  Molecular biological studies of the receptors causing these effects have indicated that 
GABA’s effects on ionic transmission (ionotropic) and metabolism (metabotropic) are mediated 
by proteins in two different super families. The first superfamily (GABAA receptors) is a set of 
ligand-gated ion channels (ligand-gated superfamily) that convey GABA’s effects on fast 
synaptic transmission. When a GABAA receptor is activated, an ion channel is opened (gated) 
and this allows chloride to enter the cell; the usual result of chloride entry is a slowing of 
neuronal activity through hyperpolarization of the cell membrane potential. 
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Fig. 2: Mechanism involved in anxiety  
  The second superfamily (GABAB) is slower, mediating GABA’s action on intracellular 
effectors through a seven transmembrane spanning receptor (serpentine superfamily) that 
modulates the action of certain guanine nucleotide binding proteins (G proteins). Through their 
activity on other effector systems, G proteins can change second messenger levels, altering signal 
transduction and gene expression, or open ion channels that are dependent on the G-protein 
subunit activities. Both excitatory and inhibitory activities are possible on a time scale that is 
longer than GABAA receptor mediated events. There is extensive heterogeneity in the structure 
of the GABAA receptor members of the ligand-gated superfamily.  
  These receptors are the targets of a number of widely used and prescribed drugs for 
sleep, anxiety, seizure disorders, and cognitive enhancement; they may also contribute to 
mediating the effects of ethanol on the body. 
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1.10 ADVERSE DRUG REACTIONS95 
  Anxiety drugs are extremely tempting, and prescribed to millions of individuals 
suffering from anxiety and stress. Contrary to popular belief, these drugs aren't necessarily as 
harmful as many people believe. They have their problems, but there are those that do benefit 
from pharmaceutical intervention - especially if they are combining that medication with some 
type of therapy. 
1.10.1 THE MAIN REASON TO AVOID ANXIETY DRUGS 
  Anxiety medicines do have some severe side effects in some cases. But it's actually not 
the side effects that are the reason to try to avoid medications. The main reason is because they 
can cause physiological and psychological dependence. This is when your body and mind 
actually start to need to drug to cope with anxiety, so that it becomes even harder to cure the 
anxiety without medication over time. 
1.10.2 COMMON SIDE EFFECTS  
  Clumping all anxiety drugs together is misleading. Some have more side effects than 
others, just like some are stronger than others. Benzodiazepines can have some fairly pronounced 
side effects, while buspirone generally has fewer, but buspirone is also much weaker which is 
why most doctors prefer to prescribe benzodiazepines. 
  Even within the benzodiazepine class there are different side effects for different 
medications. But the most common side effects of anxiety medicines are as follows: 
1. Benzodiazepines (Xanax, Valium, etc.): 
 Hypotension (low blood pressure) 
 Decreased sex drive/libido 
 Nausea 
 Lack of coordination 
 Disinhibition 
 Depression 
 Unusual emotional dysfunction, including anger and violence 
 Memory loss 
 Difficulty thinking 
 Decreased IQ 
2. Antidepressants (SSRIs, SNRIs): 
 Sexual dysfunction 
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 Headache 
 Dizziness/drowsiness 
 Diarrhea 
 Weight loss/gain 
  Both drugs may also cause what's known as "paradoxical effects," where in some cases 
the person may experience a worsening of symptoms rather than an improvement. In some, this 
may be more anxiety. In others, this can even be severe suicidal ideation and possibly even 
action. This is uncommon, but still a serious concern. 
1.10.3 DANGEROUS SIDE EFFECTS  
  Beyond the paradoxical effect of suicidal ideation and increased anxiety, it's rare for 
these drugs to show signs of truly dangerous and deadly side effects. But there are some rare 
cases of very dangerous problems from these medications, including: 
 Heart problems, especially in those with possible cardiovascular disease. 
 Persistent pulmonary hypertension (possibly fatal lung disease). 
 Increased bleeding risk. 
 Interactions with other medications. 
  Most of these are related to SSRIs. Benzodiazepines may also cause what's known as 
"dependency," which is when the body adapts to the anxiety drug. Dependency causes two 
issues. First, the medication will generally stop working (aka, "become tolerated") which means 
that you will need to find a replacement medication. 
Second, weaning off the drug incorrectly can lead to severe withdrawal symptoms. These 
withdrawal symptoms are not unlike withdrawing from severe alcoholism, and may lead to 
increased anxiety, depression, psychosis, seizures, hypersensitivity, and possibly suicide. 
Gastrointestinal problems and insomnia are also very common. Withdrawal can be extremely 
dangerous, which is why benzodiazepines often need to be slowly weaned off of over time. 
1.10.4 LONG TERM IMPLICATIONS  
  Anxiety drugs may have been given a worse reputation than they deserve. They're 
certainly not useless, and while they can cause some severe side effects, they are generally at 
least mildly well tolerated with most symptoms being distressing, but not terribly severe. 
  But when you combine the side effect risks with the physiological and psychological 
dependence risk, and the likelihood that you'll actually lose even more of your ability to cope 
with stress in the future if you depend on them, it's strongly recommended that anxiety 
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medications are used only as a last resort. If you do decide to take a medication, never take it 
alone - make sure you're also using long term anxiety reduction strategies as well so that if you 
stop taking the medication your anxiety doesn't return stronger than before. 
1.11 NEW ANXIETY MEDICATIONS IN DEVELOPMENT 96 
  The below new anxiolytics on the horizon that may be more effective and safer than 
older options. 
1. ALORADINE (PH94B) 97 
  This is a drug that has been in Phase III clinical trials since 2013 for the treatment of 
social anxiety disorder in women. It is being developed by the company Pherin Pharmaceuticals 
in the format of a “nasal spray.” Of all the treatments for anxiety disorders in the pipeline, this 
one appears to have the most promise of actually making it to market. 
  The company developing this substance is known as Pherin Pharmaceuticals and 
focuses specifically on working with “pherins” to alter neuropsychiatric and neuroendocrine 
function within humans. They have other molecules in development for the treatment of 
depression, premenstrual dysphoria, and cognitive enhancement. 
2. B-GOS 
  This is a prebiotic, or non-digestible food ingredients that improve healthy by 
stimulating the production of beneficial bacteria in the colon. It has long been thought that a 
person’s gut flora (or bacteria) may play a role in determining whether they develop a mental 
illness or experience anxiety. Additionally, there is evidence demonstrating that most 
pharmaceutical drugs (e.g. antidepressants) have detrimental effects upon a person’s gut flora. 
  Clasado Biosciences Limited currently are testing “B-GOS” in Phase I clinical trials. B-
GOS is considered a unique “trans-galactooligosaccharide” and thus far has been shown to be 
effective in the reduction of anxiety. In preliminary research, it has been found to decrease both 
“waking cortisol levels” as well as “attentional vigilance towards negative information.” 
  Some speculate that this substance may also prove to have therapeutic effects among 
individuals suffering from depression. There is mounting evidence that gut bacteria may be 
directly influencing brain function. Altering the gut microbiome may drastically change your 
mental health and/or cognition. 
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3. IW-2143 (BNC210) 
  This is an experimental anxiolytic medication undergoing clinical trials, but there’s 
currently no information regarding its mechanism of action. It has demonstrated a potent 
anxiolytic effect in animal subjects as well as in Phase I clinical trials. The good news is that it is 
unlikely to impair cognitive function, it isn’t addictive (in rodent models), and won’t make you 
feel sedated. No major side effects have been reported during the early stages of trials. 
  This drug is a “small molecule” that was discovered by the company Bionomics 
through a medicinal-chemistry program. Some evidence has shown that the molecule is capable 
of promoting “neurite” outgrowth (e.g. axon/dendrite). The company developing this drug 
(Bionomics) is a biotech company that is focused on creating therapies for CNS disorders. They 
have since licensed “BNC210” to Ironwood Pharmaceuticals, who refer to it as “IW-2143.” 
4. S32212 98 
  This is a substance that is under investigation as a potential antidepressant with 
anxiolytic properties. It functions as a selective, inverse agonist at the 5-HT2C receptor, and 
Alpha-2 adrenergic receptor antagonist. It also elicits an effect upon the 5-HT2A receptor and a 
minimal one on the 5-HT2B receptor as an antagonist. 
  The good news is that it is thought to not affect histamine or acetylcholine receptors. 
Many drugs that affect H1 histamine and mACh receptors tend to result in memory impairment. 
Should this drug ever make it to the market, it will likely be classified as an NaSSA 
(noradrenergic and specific serotonergic antidepressant); the same classification of Remeron. 
  Based on animal research, this drug elevated levels of BDNF with the amygdala and 
hippocampus of the brain. It also amplified the amount of neuronal firing within other locations, 
while increasing neurotransmitters like norepinephrine, dopamine, and acetylcholine (in the 
prefrontal cortex). It didn’t affect serotonin or histamine (which is probably a good thing). 
  Researchers have noted a variety of effects resulting from this substance including: 
antidepressant, anxiolytic, anti-obsessional, as well as anti-aggressive behaviors. It also is 
thought to enhance sleep and cognition in animals without any signs of weight fluctuation or 
diminished sex drive. Some speculate that it may even result in weight loss due to its “alpha 
blocking” effect. 
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5. SL-651,498 
  This is a drug that has long been used as an anxiolytic in scientific research, but wasn’t 
considered for human usage until 2006. In 2008, a report surfaced that preliminary human trials 
were underway and that the drug was considered as effective as Ativan in reducing anxiety, yet 
produced minimal sedation, cognitive impairment, or reduction in motor skills. This provides 
some early evidence that SL-651,498 may be an effective treatment. 
  Although its anxiolytic potential is equal to that of benzodiazepines, it is structurally 
distinct from the benzo classification. It has been classified as a “nonbenzodiazepine anxiolytic.” 
It functions as a subtype-selective GABAA agonist, and elicits primarily anxiolytic effects in 
animals (with minor sedation). Early research has also suggested that the drug is unlikely to 
produce dependence or tolerance due to its low affinity for the Alpha-5 receptor. 
1.12 HERBAL REMEDIES FOR ANXIETY99 
  Plants parts - seeds, berries, roots, leaves, bark, and flowers have been used medicinally 
by every culture. Archaeologists have found evidence that we’ve been using plants medicinally 
for at least 60,000 years! Eighty percent of the world’s population still relies on herbal remedies 
as part of their primary health care. There’s been resurgence in the use of herbs for anxiety in 
recent years. This interest has been fueled by the rising costs of prescriptions plus the awareness 
that anti-anxiety drugs like Xanax and Ativan have serious side effects, including being some of 
the most addictive substances known. 
1. ARCTIC ROOT (Rhodiolarosea) 
  Arctic root, as the name suggests, is found mainly in cold regions of the world like the 
Arctic and mountains of central China. It’s a potent adaptogen, a substance that strengthens your 
overall resistance to both physical and emotional stress. 
  This makes Arctic root particularly useful for anxiety accompanied by fatigue. 
2. ASHWAGANDHA (Withaniasomnifera) 
  Ashwagandha is one of the most important herbs in the 3,000-year-old Ayurvedic 
Hindu system of medicine. Its name literally means “smell of horse” since the root does smell a 
little horsey. Its main use now is as a stress-relieving adaptogen. It has a significant effect on the 
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stress hormone cortisol, reducing it by 25%. It is very helpful at calming anxiety of all kinds, 
especially agoraphobia (fear of open places).  
3. BACOPA (Bacopamonnieri) 
  Bacopamonnieri, sometimes called brahmi (from the word “brahman” meaning “the 
energy of universal consciousness”), is another important adaptogenic herb in Ayurvedic 
medicine.  Bacopa has a long history of use for increasing longevity and enhancing brain power. 
  It reduces anxiety while also improving memory and attention.  This makes it an 
excellent choice for anyone who has anxiety with memory loss. 
4. GINKGO (Ginkgo biloba) 
  Ginkgo biloba is one the world’s most ancient and impressive plants. The earliest 
ginkgo fossils date back 270 million years.  Ginkgo trees literally grew when dinosaurs roamed 
the earth! A handful of ginkgo trees were at the epicenter of the Hiroshima atomic bomb blast. 
Amazingly, theses trees are so hardy that they survived and are still alive today.  Ginkgo leaves 
have been used in traditional Chinese medicine for thousands of years. 
  While it’s thought of as mainly a memory enhancer, ginkgo reduces the release of stress 
hormone cortisol making it effective for anxiety and stress as well. Ginkgo raises levels of the 
neurotransmitters serotonin and dopamine which are essential for a positive mood.  
5. GINSENG (Panax ginseng) 
  Ginseng is one of the most ancient, popular and widely studied herbs on the planet. The 
Chinese believe it to be the “elixir of life” and have used it to promote strength, stamina, and 
physical performance for over 5,000 years. 
  It is usually labeled Asian, Chinese, or Korean ginseng, depending on where it is 
grown. Ginseng creates a relaxed, but alert, state. It calms you down and boosts your energy 
without being over-stimulating. It’s useful for treating stress, anxiety, fatigue, and depression. 
6. KAVA (Piper methysticum) 
  Kava (or kava kava) is a medicinal plant that originates in the South Pacific and is one 
of the most potent natural remedies for anxiety known. People throughout this region make a 
traditional kava tea that’s valued for its ability to induce a state of relaxation and mental clarity. 
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Numerous studies consistently find kava effective at treating anxiety. It’s been found to work as 
well as prescription medications for generalized anxiety disorder (GAD) by increasing the level 
of the brain chemical GABA (gamma-aminobutyric acid). 
  GABA is a relaxing neurotransmitter that calms the mind and puts the brakes on brain 
activity when needed. Low GABA is associated with numerous mental and physical disorders 
including generalized anxiety disorder, panic attacks, irritable bowel syndrome (IBS), and 
fibromyalgia. Kava should not be taken with many drugs and does not mix well with other 
natural remedies that can cause drowsiness such as 5-HTP, melatonin, gotu kola, valerian, and St. 
John’s wort.  
7. PASSION FLOWER (Passifloraincarnata) 
  Passion flower is the only herbal remedy on this list native to North America. This 
beautiful flowering vine was used traditionally by Native Americans to treat anxiety and 
insomnia. Studies have found it to be as good for treating generalized anxiety disorder as the 
prescription sedative Serax (oxazepam). It’s believed to work by increasing brain levels of 
GABA. 
8. VALERIAN (Valeriana officinalis) 
  Valerian has been called “nature’s Valium” and is mainly used to relieve anxiety, stress, 
and insomnia. It is documented use in Europe goes back more than 2,000 years its properties 
were first described by Hippocrates.  
  It’s another one of the several herbs on this list thought to work by increasing GABA 
levels in the brain. It is generally considered safe but unlike some of the other herbs for anxiety, 
valerian can definitely make you drowsy, so use it just before bedtime.Valerian can be consumed 
a tea or as a supplement, but most people stick with the supplement since valerian tea tastes and 
smells pretty awful. 
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1.13 NON PHARMACOLOGICAL TREATMENT FOR ANXIETY100 
  Anxiety disorders can be distressing and may often need therapy. The most important 
part of treatment of this condition is patient education. The guidelines especially for panic 
disorders, where patient may suffer sudden attacks without warning, recommend education for 
the family as well. The symptoms of an anxiety attack may appear similar to a heart attack or 
other medical ailments.  
  Patients as well the family needs to be educated regarding these symptoms. If a medical 
condition like high blood pressure, irregular heart rates and rhythms or overactive thyroid is 
found then appropriate medical therapy may be needed. Therapy includes psychotherapy and 
management with medications. The aim of therapy is to ensure that the patient functions 
adequately in their day-to-day life. 
1.13.1 PSYCHOTHERAPY FOR ANXIETY 
  Psychotherapy includes cognitive-behavioral therapy, anxiety management therapy and 
applied relaxation therapy. 
1.13.2 COGNITIVE-BEHAVIORAL THERAPY 
  Cognitive-behavioral therapy (CBT) is provided by a psychotherapist. Patient needs to 
be committed to therapy. Patients treated with a combination of CBT and medicines have better 
response than those who are undergoing usual treatment. Some 10 to 20 visits to the therapist are 
needed over a few weeks. For panic attacks 12 - 16 sessions over 3 - 4 months may be needed. 
These focuses towards recreating fear symptoms and help patients change their response to them.  
  In OCD for children CBT is the first choice of therapy. The therapy teaches the patient 
to identify and handle stress factors better. Patients will learn to decrease the sense of 
helplessness by shutting out or neutralizing panic-causing thoughts. He or she will be taught to 
avoid speculating that minor worries may turn to bigger problems. Relaxation techniques will be 
taught. For OCD the techniques are exposure and response prevention (ERP). 
  For patients with PTSD the psychological treatment will focus on the trauma with 
exposure therapy, cognitive therapy, and eye movement desensitization and reprocessing. Patient 
will be advised to lead a healthier lifestyle with regular exercise, adequate rest and sleep and 
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healthy balanced nutrition. They will be taught to avoid excessive caffeine and illicit drugs, 
alcohol and cigarettes. Family and social interactions to lessen the impact of the condition will be 
advised. 
1.13.3 ANXIETY MANAGEMENT THERAPY 
  Anxiety management therapy involves education, relaxation training, and exposure to 
anxiety-provoking stimuli. However, there is no positive reconstruction technique to fight 
anxiety. 
1.13.4 APPLIED RELAXATION THERAPY 
  Applied relaxation therapy helps patient relax each part of the body. The therapy takes 
12 to 15 hour-long sessions in a number of sittings and has been found to be effective. 
1.14 PSYCHOLOGICAL AND PHYSICAL STRESS MODELS 101 
  Essentially, these models induce stress by exposing the animals to psychological or 
physical challenges. These procedures may be used in acute or chronic studies depending on the 
objectives and parameter chosen by the experimenter to evaluate the impact of stress on anxiety.  
The main Stress protocols used are briefly described below. 
1. Psychosocial stress 
a. Neonatal isolation 
b. Noise stress 
c. Circadian rhythm changes 
d. Predator stress 
2. Physical stress  
a. Restraint stress 
b. Immobilization stress 
c. Temperature variation stress 
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d. Electric foot shock stress 
1.14.1 NEONATAL ISOLATION STRESS 
  Early-life stressful experiences, such as maternal separation or neonatal isolation, 
promote long-lasting neural and behavioral effects and have profound consequences on 
subsequent quality of life. 102 During the neonatal separation procedure, on the 2nd day after 
birth, the litter of the inbred strain is removed from the cage and placed in another cage for 1 
hour (9 a.m./12 a.m.) in a room located apart from the animal facility. White noise is played in 
the background to mask the vocalizations of other pups. After the 1-hour period, the litters are 
placed back with their dams in their home cages. The separation procedure is repeated for 8 days. 
This model has been used extensively to demonstrate the effect of early lifetime stress on 
vulnerability to addiction and in the generation of anxiety-like behaviors, which are usually 
observed in the adult rodents subjected to the contextual fear conditioning, EPM, or social 
interaction tests. 
1.14.2 STRESS INDUCED BY CIRCADIAN RHYTHM CHANGES 
  Alterations in circadian rhythm have a profound impact on the physical and 
psychological homeostasis of an individual. Rodents subjected to unexpected changes in the day-
night light cycle exhibit acute stress responses. Circadian rhythms are controlled by the pineal 
gland via melatonin secretion. The stress procedure consists of lighting the home cage of the 
rodents during the dark phase of the cycle (e.g., lights on from 7 p.m. to 7 a.m.) and leaving it 
unlit in the light phase (lights off from 7 a.m. to 7 p.m.). Another possibility is to promote four or 
five cycles of dark-light phases (60-180 minutes) during the circadian cycle. This is a good 
method for induction of short-term stress responses, but repeated exposure may lead to 
adaptation. Responses to this stressor can be evaluated by measuring biochemical parameters 
associated with stress response and using the previously described animal models of anxiety.  
1.14.3 STRESS INDUCED BY A NOISY STIMULUS 
  Humans are constantly exposed to potentially hazardous levels of noise in modern daily 
life. In model animals, noise stress can be induced by using loudspeakers (15 W) connected to a 
white noise generator (0-26 kHz) located 30 cm above the cage. The noise can be set at a certain 
level (e.g., 100 dB or higher) and the animals can be exposed to the noise protocol either acutely 
or repeatedly (4 hours/day/15 days). Like those of other protocols, the behavioral effects of noise 
stress can be observed in animal models of anxiety and depression.  
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1.14.4 LOW TEMPERATURE-INDUCED STRESS 
  Changes in body temperature lead to stressful responses due to activation of the 
thermoregulatory center and, subsequently, of the HPA axis. Abrupt reductions in temperature by 
using either cold water or freezer compartments have frequently been used to induce stress in 
laboratory animals. The most widely used protocols consist in the immersion of the animals in 
cold water (15-18°C for 15-30 min) or placing the animals (in their home cages) in a cold, 
isolated environment (4°C for 15-30 min). This procedure can be used in acute or chronic 
protocols (7-14 days).  
1.14.5 RESTRAINT AND IMMOBILIZATION STRESS 
  Restraint stress and immobilization protocols are one of the most commonly employed 
procedures to induce stress-related behavioral, biochemical and physiological changes in 
laboratory animals. Restraint stress is generally induced by keeping the animals in a cylindrical 
or semi-cylindrical tube with ventilation holes for 120-180 min. In an immobilization stress 
protocol, animals are restrained by gentle wrapping of their upper and lower limbs with adhesive 
tape for 120 min. Head movement is restricted by a metal loop wound around the neck. The 
procedure can be used to induce either acute or chronic stress (7-21 days). Immobilization 
models produce an inescapable physical and mental stress with a low rate of adaptation. After 
restraint or immobilization stress, animals exhibit higher levels of anxiety in the EPM and other 
tests of anxiety.  
1.14.6 ELECTRIC FOOT SHOCK-INDUCED STRESS 
  This protocol is very similar to the pre-test session described in fear conditioning-based 
models. Rodents are very susceptible to mild shocks, exhibiting a remarkable stress response 
after foot shock delivery. The protocol consists of placing rodents in a chamber with a metal grid 
floor connect to a shock generator. After a habituation period, animals receive mild (05-2 mA), 
brief (1-2 s duration) foot shocks. Like other stress protocols, electric foot shocks can be 
combined with anxiety tests.  
1.14.7 SOCIAL DEFEAT STRESS 
  The social defeat stress (SDS) model was initially proposed by Klaus Miczec. The SDS 
protocol consists of the introduction of a single mouse (known as the intruder) in the home cage 
of a resident male mouse (known as the aggressor). During the test, behaviors related to 
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confrontation of the intruder mouse by the resident aggressor are recorded. The time spent by an 
intruder mouse in social defeat posture induced by the presence of an aggressor is computed 
throughout five trials by a blind observer. Defeat posture is identified by the followed criteria: 
immobility (four paws on ground, oriented toward the aggressor), escape (escaping from the 
aggressor), crouching (four paws on ground, not oriented toward aggressor), or defensive upright 
stance (standing erect with forepaws extended). The procedure can be used in acute or chronic 
stress protocols.  
1.14.8 CHRONIC UNPREDICTABLE STRESS 
  The chronic unpredictable stress (CUS) model has been widely used to induce 
persisting stress-related behavioral changes in rodents. It consists of randomly presenting 
different stressors to the rodents on a daily basis. This scheme prevents the stress adaptation 
process observed in other models of chronic stress. In this model, animals are exposed for 2 to 5 
weeks to a wide range of stressors, including foot shocks, restraint stress, light-dark cycle 
reversal, unpleasant noises, changes in the home cage (removal of sawdust, replacement of 
sawdust with water, heating [37°C] or cooling [4°C] of the home cage). After several days of 
exposure to this regimen, the animals exhibit a gradually increased HPA axis sensitivity and a 
decrease in responses to pleasant stimuli, without; however, any change in exploratory activity.  
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2. LITERATURE REVIEW  
2.1 LITERATURE REVIEW OF ANTI-ANXIETY 
1. Anti-anxiety activity of Coriandrum sativum assessed using different experimental 
anxiety models 
Poonam Mahendra et al evaluated that extract of C. sativum at 100 and 200 mg/kg dose 
produced anti-anxiety effects almost similar to diazepam, and at 50 mg/kg dose did not produce 
anti-anxiety activity on any of the paradigm used.  
Indian J Pharmacol. 2011 Sep-Oct; 43(5): 574–577. 
2. Anti-Anxiety Activity Studies of Various Extracts of Turnera aphrodisiacaWard 
Kumar S et al investigated, petroleum ether (60–80°C), chloroform, methanol, and water 
extracts of T. aphrodisiaca aerial parts were evaluated for anti-anxiety activity in mice using 
elevated plus-maze apparatus. Among all the extracts, only methanol exhibited significant anti-
anxiety activity at a dose of 25 mg/kg with respect to control as well as standard (diazepam, 2 
mg/kg). The bioactive methanol extract was shaken with petroleum ether, chloroform, and n-
butyl alcohol, and all the shakings as well as the remaining methanol extract (RME) were further 
evaluated for anxiolytic activity. Butanol fraction and RME were found to exhibit anxiolytic 
activity in mice at the dose of 10 mg/kg and 75 mg/kg, respectively. 
Journal of Herbal Pharmacotherapy Volume 5, 2005 - Issue 4 Pages 13-21 
3. Anti-anxiety studies on extracts of Passiflora incarnata Linneaus 
Dhawan K et al evaluated that a fraction derived from the methanol extract of Passiflora 
incarnate has been observed to exhibit significant anxiolytic activity at a dose of 10 mg/kg in 
mice using elevated plus-maze model of anxiety. This fraction comprises mainly two 
components which are visible as blue and turquoise colored fluorescent spots at 366 nm of the 
UV light. The possibility of a phytoconstituent having benzoflavone nucleus as the basic moiety 
being responsible for the bioactivity of P. incarnata is highly anticipated. 
Journal of Ethnopharmacology Volume 78, Issues 2–3, December 2001, Pages 165-170 
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4. Cross-National Study of the Extent of Anti-Anxiety/Sedative Drug Use 
Mitchell B. Balter et al studied that in almost every country the percentage of females who had 
used anti-anxiety/sedative drugs was approximately twice that of males. Persons 45 years of age 
and over were over-represented among drug users in all countries in relation to their presence in 
the national population. The rank order of the countries on attitude toward tranquilizers was 
poorly correlated with rank order on use rates. However, within each country there was a sharp 
difference in attitude between users and nonusers. Independent data place the United States in a 
middle position among the nine countries surveyed on use of anti-anxiety/sedative drugs.  
The New England Journal of Medicine 1974; 290:769-774 
5. Increase of “antianxiety” activity and tolerance of behavioral depression during chronic 
administration of oxazepam 
D. L. Margules et al evaluated that Oxazepam has two opposing actions on behavior: a response 
decreasing or depressant action and a response-increasing or disinhibitory action. The course of 
the two actions in chronic dosing was determined in rats in a test in which punished and 
unpunished schedules of reinforcement were alternated. The depressant action (measured by a 
decrease in the rate of unpunished behavior) was observed to undergo tolerance after 3–4 doses, 
while the disinhibitory action (measured by an increase in the rate of punished behavior) failed to 
show tolerance and even increased throughout the chronic series. The selective tolerance of the 
depressant action is probably due to neuronal adaptation, but changes in metabolism also may be 
involved. The increase in the rate of punished behavior is attributed, at least in part, to a 
progressive unmasking of the disinhibitory action as tolerance to the depressive action develops. 
Psychopharmacologia, January 1968, Volume 13, Issue 1, pp 74–80 
6. Anti-anxiety Activity of Citrus paradisi var. star ruby Extracts 
Vikas Gupta et al reported that methanol extract at the dose of 100mg/kg of the leaves of Citrus 
paradisi var. star ruby markedly increased the average time spent in the open arms of the EPM. 
This effect was comparable to the effect produced by diazepam. Hence this plant may be 
developed as a potentially useful anti anxiety agent. 
International Journal of PharmTech Research Vol.2, No.3, pp 1655-1657, July-Sept 2010 
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7. Anti-anxiety effects of progesterone and some of its reduced metabolites: an evaluation 
using the burying behavior test 
O.Picazo et al studied that the 3α-5α metabolite of progesterone shows the highest anxiolytic 
potency in the burying behavior test, when compared with all steroids evaluated. The data are 
discussed in terms of the close structure-activity relationship requirements of steroids to 
stimulate the GABA/benzodiazepine receptor-chloride ionophore complex. 
Brain Research Volume 680, Issues 1–2, 22 May 1995, Pages 135-141 
8. Thigmotaxis as a test for anxiolytic activity in rats 
Dallas Treit et al suggested that when effects on general activity were factored out using 
analysis of covariance, the test also showed some degree of drug-class specificity, since neither 
d-amphetamine, morphine, nor chlorpromazine produced this anti-thigmotaxic effect. These 
results support an earlier report that thigmotaxis may be a useful test for anxiolytic activity in 
rats. 
Pharmacology Biochemistry and Behavior Volume 31, Issue 4, December 1988, Pages 959-962 
9. Behavioural Validation of a Light/Dark Choice Procedure for Testing Anti-Anxiety 
Agents 
Rend Misslin et al investigated about the present results indicates that this procedure can be 
considered as an unconditioned conflict paradigm based at once on the innate tendency of mice 
to seek refuge in a dark box and their propensity to escape novel places into which they have 
been forced. It is suggested that this test is particularly well adopted to measuring the 
antiaversive properties of the so called “anxiolytic” drugs. 
Behavioural Processes Volume 18, Issues 1–3, 1989, Pages 119-132 
10. Anti-anxiety effects of Apocynum venetum L. in the elevated plus maze test 
Oliver Grundmann et al evaluated that ethanolic extract prepared from the leaves of Apocynum 
venetum (AV) using the elevated plus maze (EPM) in mice results that extract is an effective 
anxiolytic agent, and suggest that the anxiolytic-like activities of this plant are mainly mediated 
via the GABAergic system. 
Journal of Ethnopharmacology Volume 110, Issue 3, 4 April 2007, Pages 406-411 
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2.2 LITERATURE REVIEW ON VACHA CHURNA 
1. Effect of Brahmyadi Churna (Brahmi, Shankhapushpi, Jatamansi, Jyotishmati, Vacha, 
Ashwagandha) and tablet Shilajatu in essential hypertension: An observational study 
Arshiya Ali et al studied essential hypertension with Brahmyadi Churna and tablet Shilajatu for 
a period of 1 month with milk as Anupana. Observation was done before the treatment, 3 mid test 
assessments on 7th, 14th, and 21st day post test assessment was done on 30th day. Intervention 
revealed that 19 had marked improvement, 14 had moderate improvement, 5 had mild 
improvement, and no improvement was noticed in 2 individuals. Reduction in blood pressure 
was observed markedly with P < 0.000. 
J Adv Pharm Technol Res. 2015 Oct-Dec; 6(4): 148–153. 
2. RATIONALITY OF SWARNA PRASHAN IN PEDIATRIC PRACTICE 
Dr. Mahapatra Arun Kumar et al in this samskara, swarna Bhasma with herbs like Vacha 
Churna (Acorus calamus ), Brahmi (Bacopa Monnieri) mixed with Honey and ghee is 
administered to the new born baby for enhancing immunity as well as for intellectual 
development. All ancient Ayurvedic texts and particularly Kashyap samhita, details of swarna 
lehan with it therapeutic utility is described. Swarna Prashan is done by various means including 
raw gold, Swarna Bhasma etc. Studies shows that by classical bhasmikaran process as described 
in texts of Ayurveda, there is reduction in the particle size of gold to dimension of about 56-57 
nm. Analysis of Various experimental studies shows that Swarna Bhasma possesses 
immunomodulatory, free radical scavenging activity, antistress activity and analgesic activity. 
Toxicity study shows that chronic administration of Swarna Bhasma is non toxic as judged by 
various laboratory and histological parameters. However, scientific evidences regarding the 
safety and efficacy of Swarna prashan in pediatric practice is lacking and hence this practice 
should be avoided or used with utmost caution. 
International Journal of Ayurvedic and Herbal Medicine 3:3 (2013)1191:1200 
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3. A comparative acute toxicity evaluation of raw and classically processed rhizomes of 
Vacha (Acorus calamus Linn.) 
Bhat, Savitha D et al reported that at 2000 mg/kg dose both raw and classically processed Vacha 
did not produce any observable toxic effects and all animals survived 14 days of observation. 
IJNPR Vol. 3(4) [December 2012], 506-511 
4. A Recent Approach for Development and Standardization of Ayurvedic Polyherbal 
Formulation (Churna) for Antioxidant Activity 
S. Ghosh D et al reported that the Physicochemical constituents found to be present in the raw 
material used the preparation of Antioxidant churna possible facilitate the desirable therapeutic 
efficacy of the medicinal formulation, and also could help in knowing the underlying 
mechanisms of Pharmacological Action. 
American Research Journal of Pharmacy, Volume 1, Issue1, Feb-2015 
5. ANTIEPILEPTIC AYURVEDIC HERBAL DRUGS – A REVIEW 
Janani et al reported that the ayurvedic herbs which are having lesser side effects in comparison 
to synthetic drugs can be a better option for the control and treatment of epilepsy .The herbs like 
Vacha, Sankhapuspi, Tagar, Shatavari, Kushtha etc. have been mentioned in the Ayuvedic 
classics for the management of Apasmara and also experimentally proved as anticonvulsant. 
Pharma Science Monitor 6(4), Oct-Dec 2015 
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3.  AYURVEDA103 
  Disease is the disturbance of ease i.e. comforts freedom from constraint, annoyance, 
awkwardness, pain or trouble both bodily and mental. Since time immemorial, man has tried to 
lead a disease free life. In one of the oldest repositories of human knowledge, vedas of Aryans 
(veda means to know, knowledge), the plants with medicinal virtues have been identified as 
oushidhis which are to be distinguished from ahara the edible plants. After vedas, further 
developments in various spheres of human life gave rise to Indian medicine called Ayurveda 
(Ayuh – life, veda – science). Dhanwantri, said to be the father of Indian medicine, lived in 7th 
century BC., as compared to Hippocrates who lived in 5th century BC. After Dhanwantri, the 
system of Ayurveda developed further, and peaked at the time of CharakSanhita and 
SushrutSanhita, the treatises on medicine and surgery written about 1000 BC to 1000 AD. 
CharakSanhita is said to be a compilation of proceedings of a symposium held in the Himalayas, 
to discuss the cure of various diseases which had originated at that time due to urbanization.  
  For this purpose, the ancient scholar divided Ayurveda into the following eight 
disciplines: 
1) Internal medicine 
2) Ophthalmology and otorhinolaryngology 
3) Surgery 
4) Toxicology 
5) Psychiatry 
6) Paediatrics 
7) Rasayana, which in broad terms means rejuvenator 
8) Vajikarna, the literal meaning is to have the sex power of a horse, but is often 
considered as fertility inducer or procreator. 
  Ayurveda, the Ancient Science of Hindus and Indians, dates back about 7000 years. It 
has eight branches, one of which is Rasayana Tantra. The word rasayana literally means the path 
that rasa takes (rasa: the primordial tissue or plasma; ayana: path) (Charaka). It is also considered 
as the science which restores youth, alleviates suffering (diseases) and bestows longevity 
(Sushruta). It is believed in Ayurveda, that the qualities of the rasa-dhatu influence the health of 
other dhatus (tissues) of the body. Hence, any medicine that improves the quality of rasa are 
called as rasayanas, resulting in the strengthening or promoting of the qualities and health of all 
tissues of the body. These rasayana plants are said to possess the following properties: 
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 Prevent ageing 
 Re-establish youth 
 Strengthen life 
 Strengthen brain and mind 
 Prevent disease 
 Promote healthy longevity 
  Rasayana Tantra appears to have been practiced as an independent clinical discipline 
primarily as a positive health medicine. With the passage of time this important branch of 
knowledge has ceased to be in practice (except the knowledge and use of a few herbs) in its 
appropriate form. Comprehensive efforts are needed to revive this useful discipline for the 
welfare of humanity at large. 
  The ability to adapt to a given habitat is a distinctive feature of all living organisms. 
Any type of demand (external or internal) in this habitat elicits either a specific or non-specific 
response.104This non-specific response to any demand has been defined as stress and the demand 
as stressor by Hans Selye. As per his description there are three stages of response to any given 
situation of stress, which together constitute the general adaptation syndrome (GAS) 105, the 
stages being  
a) alarm reaction  
b) resistance  
c) Exhaustion.  
  Thus, the ability to develop resistance and to maintain it is crucial for coping with a 
variety of stressors encountered in human life. The desire to control the coping mechanisms has 
led to the origin of the science of adaptation. The branch of Ayurveda which deals with the 
science of adaptation is called Rasayana Tantra. Ayurveda may not coin the term adaptogen, but 
those practices, or substances / herbs / medicines which help a person cope with his day to day 
stresses are known in Ayurveda as Rasayanas. Modern research has proved that herbs listed as 
Rasayanas possessadaptogenic properties as well. All of the above imply that they improve and 
increase the resistance of the body. The scientific studies carried out on most of the rasayana 
herbs showed that theseplants non-specifically activated the reticuloendothelial system (RES) 
and other components of the immune system as well. 106 
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  Knowing that the central nervous system, endocrine system and the immune system 
participate in intense crosstalk107, it was easy to hypothesize that by acting on the immune system 
these rasayanas could exert broad-based effects by initiating a massive cascade of events 
involving various neurotransmitters, hormones and amines of the stress response cycle. 
  With the emerging science of ecogenetics, it is becoming evident that genetic 
predisposition can alter responses to the external environment. However, at present most of the 
data is on diseases, which manifest in genetically predisposed persons on exposure to the external 
stressors. Can rasayanas (or adaptogens or immunomodulators) influence genetic control and 
favour the maintenance of homeostasis in stressful situations? The research on Amruta 
(Tinosporacordifolia) opens up a new vision in this direction, as early experiments have shown 
that it increases the bone marrow proliferative fractions leading to leucocytosis. A slight increase 
in dose reverses this process and inducing apoptosis, and this apparent paradox was believed to 
be because of its effect on c-myc, a gene that causes both proliferation as well as induces 
apoptosis depending on the environment.  
  These are some of the recent advances seen in the field of rasayana drugs. Looking at it 
appears that rasayana herbs act as: 
 an adaptogen 
 an immunostimulant 
 an immunomodulater 
 pro-host probiotic 
 anti-mutagenic 
  But Ayurveda has much more in it to be included under rasayana therapy. Looking at 
only a few herbs will be doing an injustice to the holistic approach of Ayurveda, hence a brief 
description of Rasayana Tantra may be necessary here. 
  According to Ayurvedic concept Rasayana therapy simultaneously affects the body and 
the mind and brings about physical and psychic improvement. This therapy prevents the effects 
of early ageing, develops intelligence and increases the bodyresistance against diseases. 
  Rasayana means vitalizing / rejuvenating. In the words of Charaka with a rasayana, one 
obtains longevity, regains youth, vitality and vigour, gets a sharp memory, intellect and freedom 
from diseases, gets a lustrous complexion and the strength of a horse. Sushruta is more specific, 
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describing a rasayana as one which is anti-ageing; increases life-span promotes intelligence and 
memory and increases resistance to disease. 
  Any drug, diet or conduct that leads to the replenishment of the dhatus and enlivens the 
body and mind is rasayana. Rasayana not only rejuvenates the body and mind, it also prevents 
disease. There are a number of drugs/materials described which possess the qualities of 
maintaining health, prolonging life and warding off diseases. They are all grouped as rasayana in 
Ayurveda. A close look at the concept of rasayana of Ayurveda and various research findings on 
rasayana suggests that rasayanatherapy/ drugmay have its effect on our ojas,immunity,resistance, 
etc.  
  Hence the following points related to the concept of resistance, immunity as described 
in Ayurveda may be useful: 
1.The qualitative, quantitative and functional balance of the body-elements maintains strength 
which, in general, causes resistance to diseases. Raktam (Blood) has been attached much 
importance because it’s normal condition reflects good health and general resistance power. 
2. Ayurveda has described a separate substance named ojas which has been said to be the essence 
of all the dhatusand is considered to be an excellent body element. Therefore, the excellence of 
the body in totality is ojas. It reflects the excellent performance of the man as a whole. Therefore, 
resistance power of the body depends on the quality and quantity of ojas. 
3. Bala (strength or power) has been classified as sahaja (natural, hereditary), kalakrita (variable 
as per age and season) and yuktikrita (acquired by good diet, drug and exercise etc.). This is why 
some families have a specific resistance to specific diseases; some diseases are born in a specific 
age and season and generally speaking those, who are well built, fall less ill. 
4. Again the bala (resistance) has been divided into vyadhi pratibandha katwa and vyadhi bala 
virodhitwabala. The former is the specific resistance against a specific disease so that those 
diseases will never afflict the man. Today, vaccines substitute this type of resistance. The latter 
does not stop the onset of the disease but can only minimise its severity. In another context it has 
been said that the overweight or emaciated, those of weak build, who have a deficient diet and 
who are mentally weak, are more susceptible to disease. 
  There are various ways of classifying rasayana therapy in Ayurveda. They are basically 
either based on the method of administering the rasayana therapy, such as 
 kutipravesika (indoor)  
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 Vataatapika (outdoor) 
 Kaamya (invigorating and vitalizing) 
 Medhya (promoting intellectual factors)  
 Achara (address psycho-somatic activities) 
 Naimittika (used to promote resistance against disease following illness)  
 Vrishya (virilifying or sex-stimulant).  
  Also remember that Rasayana Tantra is one of the eight branches (Asthanga Ayurveda) 
of Ayurveda. And, before administering rasayana the individual needs to undergo the 
shodana/panchakarma(purification therapy) process. Kaya-kalpa is nothing but another name for 
rasayana. 
3.1 WHAT ARE RASAYANA 
  The agents which cure body and mental diseases, delay old age, increase mental power, 
generating power, vital energy, eyesight, impart intelligence, memory, aid proper digestion and 
clear complexion are Rasayana.108 These nourish the whole body by strengthening the primordial 
tissue Rasa, the essence of all food we take, and which the body can assimilate. If this essence is 
well distributed in all systems, the body remains healthy. By their physio-chemical action 
  Rasayana purify and promote dhatus (tissue). They augment the body’s disease 
resistance capacity, as well as the ability for restorative reaction and counteract all the deleterious 
effects including that of ageing. 
  The Rasayana keep tissues, enzymes, membranes and tranquility of the mind in their 
normal functioning conditions through anabolic processes. They help if the tissues have become 
inactive, are to be revitalized and their composition changed. They achieve this by increasing 
bala, the physiological and immunological strength of the body. They are good for all people, at 
all stages, at all times but they do not prevent ageing and do not assure immortality. 
  Rasayana may be compared to alteratives, which work as blood cleansers by their 
diuretic and antihepatotoxic action. Alteratives also restore the proper functions of the body and 
increase health and vitality. 109They alter the body’s metabolism in various ways so that the 
tissue can best deal with the range of function from nutrition to elimination. Some of these herbs 
eliminate waste from the body through kidney, liver, lung or skin, while others work by 
stimulating digestive functions and still others act as antimicrobial agents. Some Rasayana also 
help in the disposal of waste ama. Agni is the biological fire burning inside the body, which acts 
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on food so that energy is generated by digestion. If waste is not excreted from the body properly 
and ama is deposited in the tissues, it may disturb various systems. The herbs are given to 
strengthen the tissue to counteract all the ill effects of ama. 
  In Ayurveda, human life has been divided into four spans according to growth and 
development: 
1) From birth to the age of 20, all tissues of the body grow. 
2) 20–40 years of age, tissues continue to grow. 
3) 40–60 years is the age of stagnation. If an individual has a balanced diet, cheerful life, 
adequate nourishment, and is free of worries and anxiety, the person can maintain good 
health. At this stage the mental activities expand, and power of judgment increases. 
4) After the age of 60, in spite of good quality of life, senescence starts. Metabolism of the 
tissues decreases, waste is not excreted properly, and the bone joints become dry and 
fixed. 
  The body can be rejuvenated at stages 3 and 4 and during senescence by Rasayana. 
These can be used as a dietary supplement, but in the case of chronic diseases, old age, etc. 
where kaya kalp (rejuvenation) is required, a special treatment, called Rasayana therapy, is 
provided under the supervision of medical experts. 
3.2 RASAYANA THERAPY 
  Before the start of actual therapy, the internal and external organs of the body are 
cleansed and the system is made more receptive to assimilation of medication. It has been 
stressed that Rasayana administered without these treatments is like seed sown on barren land, 
from where no good results can be expected. This pretreatment is given only to those persons 
who have enough strength to bear it. 
3.3 PRE-TREATMENT FOR RASAYANATHERAPY 
3.3.1 SAMSHODHNA (Diet restriction) 
  One week before the start of therapy, the person should resort to a simple diet 
consisting of only steamed vegetables and fresh fruits. He should not be given sugar, alcohol or 
animal products. Milk and honey are allowed. 
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3.3.2 PURVAKARMA (Preparatory treatment) 
  Involves massage with warm oil, and application of heat on the body by a massage 
therapist. The massage should be so vigorous that a large amount of latent heat of the body is 
generated. For this purpose sesame oil is generally used but sometimes some other medicated 
oils, which are supposed to have better properties, are applied. 
3.3.3 PANCHKARMA (Cleansing of internal organs of the body) 
Virechna  : purging to clean the small intestine 
Basti  : to clean the large intestine 
Vamna  : emetics to clean the stomach 
Naysya  : nasal drops to clear the respiratory passage 
Raktaoksha : Bloodletting by leeches may be done to those patients who have excess of 
blood in their body. Nowadays blood is donated to the blood bank. It is optional. 
3.4 ADMINISTRATION OF HERBS 
  After panchkarma the patient is admitted into a hut (kutiprveshika) for the 
administration of Rasayana preparations. The hut should be in a pollution-free area, well 
ventilated, facing north, and painted with slaked lime to make it germ-free. 
  The preparations required during Rasayana therapy vary, at the discretion of the health 
provider. Generally the patient is given a restricted diet, along with only that quantity of 
medication which the patient can easily digest. The medicine should be fully utilized by the body 
and not passed into faeces undigested. The medicine should not create any digestive disturbance, 
such as indigestion, hyperacidity or constipation. If any of these conditions persist for some time, 
a laxative or a colon cleanser should be given. 
  Herbs such as garlic, neem, amalaki, etc. were commonly used for this therapy but now 
polyherbal preparations with animal products such as musk, amber, coral, pearl, gems, minerals, 
and metals are prescribed. Some of the formulations may consist of red sulphide of mercury, 
prepared in the presence of gold, along with processed poisonous herbs like aconite, nux vomica, 
etc. The preparation is given to the patient in the early hours of the morning (within three hours 
of sunrise). During administration of mercurial compounds, the patient should have a pure 
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vegetarian diet. He should not remain thirsty or hungry. He should avoid excessive sleep, 
swimming, talking, anger, sadness, desire, excessive happiness, bathing, worry, irritation, 
depression, sex, and fragrances. He should lead a simple, pious, and religious life. 
  After kutiprevesh, the patient should start steadily with a diet of rice water, followed by 
rice gruel, rice and split beans, rice with beans, and finally he may be given a normal diet with a 
teaspoonful of ghee (butter oil). The patient should remain in a relaxed condition, and should 
have a whole body massage daily with warm sesame oil. This treatment is said to make the 
arteries softer and smoother, the constitution of the blood changes, clots are dissolved, and new 
cells are formed. 
3.5 RASAYANA PREPARATIONS 
  The simplest mode of administering an herb is to take it as it is, to pound it or to use its 
juice after filtration. These are the least processed forms and all constituents of the herb are made 
available to the body. However fresh herbs are often not readily available throughout the year. 
Some fresh herbs not only taste bad but are even nauseating. The best alternative to fresh herbs is 
to use properly dried herbs in powder form (churn). Usually the churn is mixed with salt or 
sugar to make them more palatable. These powders are usually administered with a fluid 
medium, because in a dry form they are difficult to swallow or sometimes may even choke the 
respiratory passage. For Rasayana powders, the common medium for administration is boiled 
lukewarm cow’s milk, sweetened with sugar, honey, cow’s ghee or a mixture of both milk and 
ghee. (Ghee is prepared by heating the butter to remove the fat-insoluble, proteinaceous and 
other matters and water, so that only fatty acids and the constituents soluble in fat are left. It is 
surprising to find that though butter has been a common household item in India since ancient 
times, it has rarely been used for the administration of Ayurvedic preparations.) 
  The other methods of administration of powdered herbs are infusion, decoction and 
distillation. To make an infusion, the herb is immersed in water, usually kept overnight, filtered 
and used. In decoction the herb is boiled in water until the water is reduced to half or so, filtered 
through a cheese cloth and heated further until the decoction is reduced to one-fourth. The 
infusion or decoction may be used in place of juice, if fresh herbs are not available. For 
distillation, fresh leaves or flowers, dry root or seed are boiled in water in a closed container and 
the steam that arises is condensed, so that the volatile active constituents of the herb are dispersed 
in water (aqua). 
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  Ghansatva are concentrated, sometimes standardized aqueous extracts of the herbs 
made from the decoction in the form of a thick paste or dry powder. These are now preferred by 
the pharmaceutical industry because they reduce the bulk of the herbs, and can be easily 
incorporated into capsules or pills, are easy to formulate, have a longer shelf life and the end 
products have good consumer appeal. Sometimes syrups or alcoholic preparations are made from 
these extracts. 
  The herbal products, in general, have an expiry period of one year but if stored in 
airtight containers they may be used for up to two years, whilst the mineral products may be used 
indefinitely. The early Ayurvedic physicians were aware that the aqueous decoctions did not 
extract all the constituents from the herbs, so they developed methods to generate alcohol from 
the solvent during fermentation, in which ethanol soluble constituents of the herbal mixtures 
could be dissolved. These preparations are called Asav and Arishta, to which sweetening agents 
such as raw sugar, honey and 
  Rasayana preparations flowers of Woodfordiafloribunda,etc., which can be fermented 
easily, are initially added. Due to the alcohol these preparations have a long shelf life, taste good 
and provide immediate energy and therapeutic agent to the body. Asava and Arishta differ in 
their method of preparation. Arishta are prepared from the decoctions of the herbs, whereas Asav 
are made from dry powders. In both cases all the herbs are allowed to ferment in airtight earthen 
pitchers for 40–50 days. Before the fermentation of herbal materials it is ensured that the pots are 
clean. They are then fumigated with camphor, sandal and agar wood (Aquillariaagallocha), or 
with long pepper powder and ghee. The water to be used should not be alkaline and should be 
free of inorganic matter. When the period of fermentation is complete, the solution is filtered and 
stored in bottles. The fermented end product mainly consists of ethanol, glycerol, lactic acid, 
acetic acid, besides other products. This can be used for an indefinite period. In a study of 
Draksharishta, it was seen that before fermentation the mixture contained 34.91 per cent sugar, 
but after fermentation the product had 19.17 per cent sugar, 8.70 per cent, alcohol, 0.24 per cent 
glycerin, 0.21 per cent lactic acid and 1.38 per cent acetic acid. The pH of the medium changed 
from 6.40 to 5.00. 
  Avleha or lehya (linctus) are semi-solid preparations prepared from dry powders, 
decoctions and the pulp of the herbs, along with sugary substances, honey, ghee and/or oil. 
During preparation, sugar is boiled in the extract/decoction of the herbs or water, until thick in 
consistency. A fine powder of herbs, minerals and spices is then added to warm thick syrup and 
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stirred so that a homogenous mixture is formed, followed by ghee or oil when still hot. Honey 
should be added after cooling the preparation. Avleha should be dried to such an extent that there 
is neither too little nor too much moisture. 
  The term Bhasam literally means ash. In practice, in this case, minerals, gems or hard 
animal products, after treatment with herbs, are calcined at a very high temperature to form ash 
and then this ash-like end product is heated and powdered repeatedly. When this process has 
been repeated 100 times, the bhasam is known as Shatputi (shat is hundred) but after 1,000 times 
it is known as Sahastraputi (sahastr is thousand). For each mineral or exoskeleton of animals, 
different methods are followed. These products do not degrade during storage and can be used 
indefinitely. 
  Ghrita or Ghritam are preparations made from oil or ghee. These contain fat soluble 
constituents. Ghrita are prepared by heating juice, paste, decoction, infusion, etc. of the herbs in 
ghee and oil until all the water evaporates. The resulting mass is filtered to remove fat insoluble 
materials. The fat is preserved for use as a medicine. Where vegetable oils alone are used, 
heating is stopped when froth appears, but when ghee is used, heating is stopped when the froth 
subsides. For internal uses these preparations can be stored for sixteen months after manufacture, 
but for external use there is no expiry period. 
  Pak are the preparations made from milk, ghee, dry fruits, herbs, minerals and spices. 
These preparations are mainly used as nutrients or aphrodisiacs. The usual method for their 
preparation is to boil milk until thick and solid. This condensed milk is fried in ghee and sugar 
powder or thick sugar syrup, herbs, minerals, chopped dry fruits and spices, etc. are added to it 
when warm. The whole mass is made into chocolate or candy balls of about 25 g each. 
  Before use poisonous herbs or minerals are subjected to mitigation called marn (to kill) 
or sodhana to purify but it is actually a process to reduce the toxicity so as to make them 
available to the body within safe therapeutic doses. 
  In this process toxic materials are generally boiled or treated with some herbs or 
chemicals in fluids such as cow’s urine, cow dung solution, water, milk, etc. After treatment the 
herb/mineral is dried and processed further before use. 
  In India, cane sugar juice is used for making raw sugar (brownish in colour) and for 
sugar manufactured by western technology. In addition to these, an indigenous method of 
refining sugar has been used for a very long time. The end product, called Mishri, consists of 
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lumps of transparent, bold crystals. This sugar candy is considered to have a cooling effect and is 
used in auspicious ceremonies and in Ayurvedic medicaments as a sweetening agent. In the 
present book, the term sugar candy has been used for Mishri, to differentiate it from other forms 
of sugar. 
  In Ayurveda five types of salts are recognised. Out of these a man-made preparation 
called black salt is considered a good carminative and is included in many formulations for 
digestive problems. It is prepared by fusing saltpetre (nitre), Terminalia chebula, and common 
salt. In the presence of organic matter at high temperatures the salt turns into a deep violet 
amorphous mass. 
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4. VACHA110 
Vacha is also called Calamus and Sweet Flag in English and Botanically, AcorusCalamus. is a 
potent nootropic herb. 
 
       Fig. 3: Acorus Calamus 
4.1 BOTANICAL CLASSIFICATION 
Kingdom   - Plantae 
Sub-Kingdom   - Viridiplantae 
Infra Kingdom  - Streptophyta (Land Plants) 
Super division   - Embryophyta 
Division     - Tracheophyta (Tracheophytes or Vascular Plants) 
Sub Division   - Spermatophytina (Spermatophytes or Seed Plants) 
Class    - Magnoliopsida 
Super Order   - Lilianae (Monocots or Monocotyledons) 
Order    - Acorales 
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4.2 BOTANICAL DESCRIPTION 
  Vacha is the Hindi Name of Calamus root, also known as Sweet Flag in English. 
Botanically, it is Acorus Calamus, which belongs to the Acoraceae (sweet-flag). 
Botanical Name  - Acorus Calamus 
English Name  -  Calamus, Sweet Flag 
Hindi Name  - Vacha, Vach 
Ayurvedic Name - Vacha, Ugargandha, Chhadgrantha 
Hindi   - Bach, Gora-bach 
Tamil   - Vasambu, Pillai maruntho 
Telugu   - Vasa 
Kannada   -  Baje, Narru Berua 
Malayalam  - Vayambu 
4.3 THE PLANT AND ITS DISTRIBUTION 
  This herb originated in east Europe and adjoining areas. In India it grows in marshy and 
humid land in many places. It has sword-like leaves, arranged in a rosette, from the centre of 
which a bunch of blue or violet flowers may arise, hence the name blue flag. The root is about 1 
cm thick, spreads prostrate within the soil and has distinct nodes and internodes. Numerous root 
fibers arise all over the internodes. 
  During collection, the root is removed from the soil, cut into 5 cm long pieces and 
dried. On drying it becomes rather flat with longitudinal striations. The central vascular portion is 
darker than the rest of the root. It has a distinct strong aromatic odour. 
  In Indian it is known as vachaor ghorvachaand it is distinguished from balvachaor 
parsikvacha (khurasanivacha) which does not have a central darker portion and is white 
throughout. It is obtained from Iris germanica L, which is cultivated in graveyards of Muslims in 
Kashmir. It is said that the root’s smell keeps predators (rats) away, which would otherwise prey 
on the dead bodies.  
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4.4 DESCRIPTION 
4.4.1 MACROSCOPIC 
  Drug occurs in simple or rarely with thumb-like branches at nodes; sub cylindrical to 
slightly flattened, somewhat tortuous or rarely straight, cut pieces of 1-5 cm long, and 0.5-1.5 
cm thick; upper side marked with alternately arranged, large, broadly, triangular, transverse leaf 
scars which almost encircle the rhizome; at nodes leaf sheath mostly having an appearence 
present; lower side shows elevated tubercular spots of root scars; light-brown with reddish-tinge 
to pinkish externally, buff coloured internally; fracture, short; odour, aromatic; taste, pungent 
and bitter. 
4.4.2 MICROSCOPIC  
  Rhizome - Shows single layered epidermis; cortex composed of spherical to oblong, 
thin-walled cells of various sizes, cells towards periphery, smaller, somewhat collenchymatous, 
more or less closely arranged cells towards inner side, rounded and form a network of chains of 
single row of cells, enclosing large air spaces, fibro-vascular bundles and secretory cells having 
light yellowish-brown contents, present in this region; endodermis distinct; stele composed of 
round, parenchymatous cells enclosing large air spaces similar to those of cortex and several 
concentric vascular bundles arranged in a ring towards endodermis, a few vascular bundles 
scattered in ground tissues; starch grains simple, spherical, measuring 3-6 µ in diameter, present 
in cortex and ground tissue. 
  Powder - Buff coloured; shows fibres, reticulate, annular vessels and simple spherical 
starch grains, measuring 3-6 µ in diameter.  
4.5 PHARMACOLOGICAL ACTIONS 
  Vacha (Acorus Calamus) has a wide range of therapeutic uses. It has antispasmodic, 
carminative and digestive properties, which helps in the treatment of the abdominal diseases. It 
has stimulant action on the mind and increases attention span and concentration. Anti-
inflammatory and analgesic actions help in arthritic disorders especially rheumatoid arthritis. 
Overall, it improves blood circulation and mitigates the inflammation. 
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4.6 MEDICINAL PROPERTIES 
 Neuroprotective 
 Anticonvulsant 
 Antidepressant 
 Nervine Stimulant 
 Nootropic 
 Sedative 
 Muscle relaxant 
 Analgesic 
 Anti-arthritic 
 Anti-inflammatory 
 Antitussive 
 Antibacterial 
 Anti-hypertensive 
 Cardiac Stimulant 
 Cardio protective 
 AamPachak (Detoxifier) 
 Carminative 
 Antispasmodic 
 Cholagogue 
 Digestive Stimulant 
 Emmenagogue 
 Intellect promoting 
 Thermogenic (produces heat in the body) 
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4.7 AYURVEDIC PROPERTIES 
RASA (Taste) KATU (Pungent), TIKTA (Bitter) 
ANU RASA (After Taste) KASAYA (Astringent) 
GUNA (Main Quality) LAGHU (Light), TIKSHNA (Sharp) 
VIRYA (Potency) USHNA (Hot) 
VIPAKA (Resultant) KATU (Pungent) 
PRABHAVA (Action) Nootropic 
DOSHA KARMA (Effect on 
Humors) 
Pacifies KAPHA & VATA and increases 
PITTA 
Dhatu (Tissue) Effect RASA, RAKTA, MEDAS, ASTHI 
Organs Effect 
Brain, Vocal Cord, Stomach, Liver, Lungs, & 
Uterus 
Main Indication Skin Disorders 
 
  According to ayurvedic point of view, it is good for Vata and Kapha disorders and it 
should be avoided in Pitta dominance and increased Pitta symptoms. 
4.8 VACHA (CALAMUS) INDICATIONS 
When used as tonic, Vacha (Calamus) root helps to increase:- 
 Memory 
 Cognition 
 Intelligence 
 Confidence 
 Digestive fire 
 Lifespan 
Vacha (Calamus) root is widely used for many ailments and some of them are listed below: 
Mind, Brain & Nerves 
 Memory Loss 
 Mental Fatigue 
 Headache 
 Epilepsy 
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 Schizophrenia 
 Anxiety 
 Depression with passive symptoms 
 Postpartum depression 
 Paralysis 
 Delayed speech and language milestones in children 
Abdomen 
 Diseases due to accumulated AMA (toxins from undigested foods or particles) 
 Loss of appetite 
 Loss of desire to eat 
 Constipation (due to excess AMA) 
 Flatulence 
 Abdominal cramps 
 Piles 
 Worm infestation – intestinal worms 
 Irritable bowel syndrome 
 Bad breath 
 Diarrhea 
Respiratory System 
 Productive cough 
 Upper respiratory tract infection and fever due to it 
 Hiccup 
 Asthma 
 Common cold or Flu 
Muscles, Bones & Joints 
 Fibromyalgia or muscle pain 
 Frozen shoulder 
 Rheumatoid arthritis 
Heart & Blood Vessels 
 Tachycardia 
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 Hypertension 
Women’s Health 
 Dysmenorrhea 
 Oligomenorrhea 
4.9 SIDE EFFECTS 
  The most common side effect of Vacha (sweet flag) is headache, which generally 
occurs in people with increased Pitta Dosha in their body. 
1. Headache (common in people with Pitta Constitution or having Pitta disease) 
2. Nausea 
3. Vomiting (occurs only with higher dosage i.e. more than 1 gram) 
4. Low blood pressure (uncommon with Calamus root powder, but common with Calamus oil) 
5. Bradycardia – slow heartbeat 
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5. SCOPE OF WORK 
  There are an estimated 40 million people above age 18 that suffer from anxiety, clearly 
more emphasis will be placed on coming up with treatments will be burden 
  There are currently many different types of medications that can be utilized to treat 
anxiety. The problem is that many of the drugs are poorly tolerated and/or produce significant 
unwanted side effects.  
  The most effective class of drugs to treat anxiety is the benzodiazepines as they provide 
rapid and significant relief but the problem with the benzodiazepines is that they impair cognitive 
function while consuming them, and long-term usage could lead to permanent memory 
impairment.  
  Most people end up preferring alternative treatment such as natural cures for anxiety 
like  
 Meditation practice such as Ayuveda, Siddha and Homeopathy 
 Participating in cognitive behavioral therapy (CBT),  
 Reducing stress 
 Exercise. 
There are people that have explored every logical method of biohacking their mental health and 
have still not been able to find relief. Sometimes people may genuinely need a medication to help 
them cope with their reality. So an effort has been made to validate the effect of ayurvedic 
preparation Vacha Churnam 
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6. PLAN OF WORK 
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7. MATERIALS AND METHODS 
7.1 COLLECTION  
The marketed product vacha churna were bought from online shopping website Ayus vastha 
 
7.2 PREPARATION OF VACHA CHURNAM: 
The required amount of drug was dispersed in distilled water and was administered orally to mice 
by using intra-gastric catheter. 
The preparation was freshly prepared on daily basis till the termination of experiment. 
 
 
      
      Fig. No: 4 Vacha Churnam 
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8. PRELIMINARY PHYTOCHEMICAL ANALYSIS 
111 
  Vacha churna was subjected to preliminary phytochemical screening for the presence 
or absence of phytoconstituents by the following methods. 
1. TEST FOR ALKALOIDS: 
Vacha Churna was treated with diluted HCl and filtered. The filtrate was treated with various 
alkaloidal agents. 
Mayer’s Test: Sample was treated with Mayer’s reagent; appearance of cream color indicates 
presence of alkaloids.  
Dragendroff`s Test: Sample was treated with Dragendroff`s reagent, appearance of reddish 
brown precipitate indicates presence of alkaloids.   
2. TEST FOR CARBOHYDRATES: 
Fehling`s Test: To the sample Fehling`s solution A and B was added and heated for two minutes. 
Appearance of reddish brown color indicates presence of reducing sugars.  
3. TEST FOR PROTEINS:  
Biuret`s Test: To Vacha Churna, add copper sulphate (CuSO4) solution followed by sodium 
hydroxide solution, a violet color precipitates indicates presence of proteins.  
4. TEST FOR STEROIDS:  
Liebermann Burchard`s Test:  
Vacha Churna was treated with concentrated Sulphuric acid (H2SO4) and glacial acetic acid 
followed by acetic anhydride, a violet ring appears at the junction of the liquids and appearance 
of green color in the aqueous layer indicates presence of steroids. 
5. TEST FOR PHENOLS: 
Vacha Churna was treated with neutral ferric chloride solution and few drops of alcohol, 
appearance of bluish green or red color indicates presence of phenols. 
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6. TEST FOR TANNINS: 
Vacha Churna was treated with 10% lead acetate solution appearance of white precipitate 
indicates presence of tannins.  
7. TEST FOR FLAVONOIDS: 
Vacha Churna was hydrolyzed with 10%sulphuric acid and cooled. It was then extracted with 
diethyl ether and divided in to 3 portions in three separate test tubes.1ml of diluted sodium 
carbonate, 1ml of 0.1 N sodium hydroxide and 1 ml of diluted ammonia solutions were added to 
the first, second and third test tube respectively. Development of yellow color in each test tube 
indicates presence of flavonoids. 
Shinoda’s test:  
Vacha Churna dissolved in alcohol, to which a piece of magnesium followed by drop wise 
addition of concentrated hydrochloric acid and heated. Appearance of purple color indicates 
presence of flavonoids. 
8. TEST FOR GLYCOSIDES: 
Vacha Churna was mixed with a little anthrone on a while on a watch glass.one drop concentrated 
Sulphuric acid was added made into a paste and warmed gently over water bath. 
9. TEST FOR SAPONINS: 
Foam test: Vacha Churna was diluted to 20 ml with distilled water, formation of foam in the 
upper part of the test tubes presence of saponins. 
10.  TEST FOR TERPENES: 
Vacha Churna were treated with tin and thionyl chloride, appearance of pink color indicates 
presence of Terpenes. 
Study Of Anxiolytic Activity In Mice Using Vacha Churanam (Rasayana Preparation- Ayurvedic System Of Medicine) 
 
Department of Pharmacology Page 67 
 
9. ACUTE TOXICITY STUDIES: 112 
             The acute toxicity was done by using OECD guidelines 423.The acute toxic class 
method (423) was step wise procedure with 3 animals of single sex per step. Depending on the 
mortality and/or morbidity status of the animals, on the average 2-4 steps may be necessary to 
allow judgment on the acute toxicity of the substances. This procedure results in the use of a 
specified number of animals while allowing for acceptable data- based scientific conclusion. 
This method uses defined doses of drug (2000mg/kg body weight) and results allow a substance 
to be ranked and classified according to the Globally Harmonized System (GHS) for 
classification of chemical which cause acute toxicity. 
9.1 PROCEDURE: 
  Adult female Swiss albino mice weighing 20- 30gms were used for the study. The 
starting dose level of 2000mg/kg body weight p.o of vacha churna was given. Since most of the 
crude extracts possess LD50 value more than 2000 mg/kg, p.o. so starting dose 2000mg/g p.o. 
was used. Dose volume administered was 1ml/100 gm body weight to mice which were fasted 
overnight with water ad libitum. Food was withheld for further 3-4hrs after oral administration 
of drugs and observed for the signs of toxicity. 
  Body weight of each mice before and after administration of vacha churna was noted 
and any changes in skin and fur, eyes and mucous membrane, respiratory, circulatory, autonomic 
& central nervous system, motor activity and behavior pattern was observed and also sign of 
tremors, convulsion, salivation, diarrhoea, lethargy, sleep and coma was noted. The onset of 
toxicity and signs of toxicity was also noted. 
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10. EXPERIMENTAL ANIMALS 
The Swiss albino mice weighing 22-30gm were used for this study. The inbreed animals were 
procured from the animal house of C.L. Baid Metha college of pharmacy, Thoraipakkam,  
Chennai-  97.They  were  housed  six  per  kg  under  standard  laboratory conditions at a 
temperature 22±2°C with 12:12 hrs light and dark circle. The animals were provided with 
standard animal feed, water and ad libitum. The animals were adapted to laboratory conditions 
one week prior to initiation of experiments. All experiments were carried out according to 
the guidelines for care and use of experimental animals and approved by Committee for the 
Purpose of Control and Supervision of Experiments on Animals (CPCSEA). The study was 
approved by Institutional Animal Ethical Committee (IAEC) 
10.1 EXPERIMENTAL DESIGN: 
On the first day of experiment the animals were divided randomly into five groups of six 
animals each. Anxiety is induced by low temperature-induced stress for the II, III, IV, V groups 
and continued for 10 days. 
 Control animals were given distilled water orally by using intragastric catheter, the last dose 
was given 60 min prior to behavioral testing and on 21st day sacrification of animal were done 
for in vitro studies. 
IAEC REFERENCE NO: IAEC/LI/01/CLBMCP/2017 
 
10.2 GROUPING 
 
S.NO GROUPS TREATMENT 
1 Group I Control 
2 Group II Negative Control 
3 Group III Standard (Diazepam 5mg/kg,i.p) 
4 Group IV Low dose (200mg/kg,p.o) 
5 Group V High dose (400mg/kg,p.o) 
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11. METHODS AND ASSESSMENTS 
11.1 LOCOMOTOR ACTIVITY TEST:  
 Locomotor activity (horizontal activity) was measured using Actimeter. 
Actophotometer which operates on photoelectric cells connected with a counter.  
 When a beam of light falling on the photocell is cut off by the animal a count is 
recorded and displayed digitally.  
 Each mice was placed individually in the activity cage floor for 10 min and the 
locomotion count was directly read from the digital reading displayed in the 
actimeter. 
 Actimeter is the combination of hole board and actophotometer in which both rats and 
mice can be placed. 
11.2 ELEVATED ZERO MAZE: 113 
 Elevated zero maze is a modification of the elevated plus maze model of anxiety in 
mice, which incorporates both traditional and novel ethological measures in the 
analysis of drug effects. 
 The elevated zero-maze constitutes a modification in both design and procedure 
which aims to improve upon the traditional model by increasing the sensitivity to, and 
facilitating interpretation of, drug action. 
 The novel design comprises an elevated annular platform with two opposite, enclosed 
quadrants and two open quadrants, and addresses one potentially problematic issue 
inherent in the plus-maze design, i.e., the unavoidable ambiguity associated with time 
spent on the central square, removing any ambiguity in the interpretation and allowing 
uninterrupted exploration. 
 Transfer latency was defined as the time (in seconds) taken by the animal to move 
from the open arm into one of the covered arms with all its four legs. 
11.3 DARK-LIGHT COMPARTMENT: 114 
 The apparatus used for the light/dark transition test consisted of a cage (21x42x25 
cm) divided into two sections of equal size by a partition with door.  
 Mice are housed six per cage in a room with a 12 hr light/dark cycle (lights on at 7:00 
A.M.) with ad libitum access to food and water.  
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 All the cages containing rats are transferred to the behavior testing room 30 min 
before the first trial begins.  
 One chamber is brightly illuminated by white diodes (390 lux), whereas the other 
chamber is dark (2 lux).  
 Mice are placed into the dark side and the door is opened manually 3 seconds.  
 The door is used so that the mice do not enter the light chamber immediately after the 
release with their motivation to escape from experimenter, since the latency to enter 
the light chamber may serve as an index of anxiety-like behavior.  
 Mice are allowed to move freely between the two chambers with door open for 10 
min. 
 The total number of transitions, the time spent in the each chamber, no of rearings and 
the latency to enter the light chamber is recorded manually.  
 After each trial, all chambers are cleaned with super hypochlorous water to prevent a 
bias based on olfactory cues. 
11.4 MARBLE BURYING BEHAVIOR: 115 
 Place one mice into a corner of the cage containing marbles, being careful to place the 
mice on bedding as far from marbles as possible, and place the filter-top cover on the 
cage. 
 Withhold food and water during the test. Allow mice to remain in the cage 
undisturbed for 30 min.  
 Remove the mice and return it to its home cage after test completion, taking extreme 
care not to move or dislodge the marbles in the process of removing the subject from 
the cage. 
 Score a marble as buried if two-thirds of its surface area is covered by bedding.  
 Average scores for the number of marbles buried for each mice was recorded 
manually. Retrieve all 20 marbles from the bedding. Dispose of bedding. 
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12. NEUROTRANSMITTERS ESTIMATION 116  
PREPARATION OF TISSUE EXTRACTS:  
REAGENTS : 
 HCl-butanol 
 Heptanes 
 0.1M HCl: (0.85ml conc. HCl upto 100ml of water) 
PROCEDURE: 
  On the day of experiment mice were sacrificed, whole brain was dissected out and 
the subcortical region (including the striatum) was separated. Tissue was weighed and 
homogenized in 5ml HCl-butanol for about 1 min followed by the sample was then centrifuged 
for about 10 min at 2000rpm. An aliquot supernatant phase (1ml) was removed and added to 
Eppendorf tube containing 2.5ml heptane and 0.31ml of 0.1M HCl. After 10 min of vigorous 
shaking, the tube was centrifuged under the same conditions as above in order to separate two 
phases, and the overlaying organic phase was discarded. The aqueous phase (0.2ml) was then 
taken for the dopamine, serotonin and norepinephrine assay. All the steps were carried out at 
0°C. it was taken in between 50-75 mg of the tissue for homogenate with 5ml of HCl-butanol in 
correlation of same tissue concentration of 0.1ml of HCl-butanol in Schlumpf method. 
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12.1 ESTIMATION OF DOPAMINE: 
REAGENTS: 
 0.4M HCl: 3.4ml conc. HCl upto 100ml water 
 Sodium acetate buffer pH (6.9) 
 5M NaOH 
 0.1M Iodine solution ( in ethanol) 
 Sodiumthiosulphate 
 10M acetic acid: 57ml of glacial acetic acid dissolved in distilled water upto 100ml. 
PROCEDURE: 
 To the 0.2ml of aqueous phase, 0.5ml 0.4M HCl and 0.1ml of EDTA/sodium acetate 
buffer (pH6.9) were added, followed by 0.1ml iodine solution (0.1M in ethanol) in oxidation. 
The reaction was stopped after 2 min by addition of 0.1ml Sodium thiosulphate solution. 0.1ml 
acetic acid is added after 1.5 min. the solution was then heated to 100°C for 6 min when the 
sample again reached room temperature, excitation and emission spectra were read from the 
spectrofluorimeter. The readings were taken at 330-370nm. 
Unknown Conc. =   Intensity of unknown * Conc of Std 
     Intensity of Std 
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12.2 ESTIMATION OF SEROTONIN: 
 The serotonin content was estimated by the method of Schlumpf. 
REAGENTS: 
 O-Phthalaldialdehyde (OPT) reagent 
PROCEDURE: 
 To 0.2ml of aqueous extract 0.25ml of OPT reagent was added. The flurophore was 
developed by heating to 100°C for 10 min. after the samples reached equilibrium with the 
ambient temperature, readings were taken at 360-470nm in the spectrofluroimeter. For serotonin 
tissue blank, 0.25ml conc. HCl without OPT was added. Internal standard: 500μg /ml each of 
noradrenaline, dopamine and serotonin are prepared in distilled water: HCl-butanol in 1:2 ratios. 
Unknown Conc. =   Intensity of unknown * Conc of Std 
     Intensity of Std 
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12.3 DETERMINATION OF ACETYLCHOLINESTERASE (ACHE) ENZYME 117 
Acetylcholinesterase enzyme activity was estimated by Elman method.  
REAGENTS  
1. 0.1M phosphate buffer  
2. DTNB Reagent  
3. Acetylthiocholine (ATC)  
PROCEDURE  
The mice were decapitated,brains are removed quickly and placed in ice cold saline. 
Frontal cortex, hippocampus and septum are quickly dissected out on a petri dish chilled on 
crushed ice.the tissues were weighed and homogenized in 0.1M phosphate buffer( pH 8).0.4ml 
aliquot of the homogenate is added to a cuvette containing 2.6ml of phosphate buffer(0.1M,pH 
8) and 100μl of DTNB. The contents of the cuvette are mixed thoroughly by bubbling air and 
absorbance is measured at 412nm in a spectrophotometer. When absorbance reaches a stable 
value,it is recorded as basal reading.20μl of substrate i.e., acetylthiocholine is added and change 
in absorbance is recorded. Change in absorbance/min is thus determined. 
 
Reagents  Sample  Blank  
Phosphate buffer 
solution  
2.6ml  2.7ml  
Supernatant  0.4ml  0.4ml  
DTNB  0.1ml  ……  
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CALCULATIONS  
The enzyme activity is also calculated by using the following formula  
                                                                      
 A/min X Vt  
Acetylcholinesterase activity (M/ml) = -----------------------  
ε X b X VS  
where, 
 
A/min= Change in absorbance per min 
 
ε= 1.361x 104 M/cm 
 
b= path length (1cm) 
 
Vt= total volume (3.1ml) 
VS= sample volume (0.4ml) 
The final reading of enzyme activity is expressed as μ moles/min/mg tissue 
 
μ moles/ml sample 
 
μ moles/min/mg protein= ------------------------------------------- 
mg protein/ml sample dilution 
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13. ESTIMATION OF ANTIOXIDANT ENZYME 
13.1 ESTIMATION OF SUPEROXIDE DISMUTASE (SOD) 118 
REAGENTS: 
 Carbonate buffer (100mM, pH 10.2) 
 Epinephrine (3mM) 
PROCEDURE: 
  The SOD activity in supernatant was measured by the method of Misra and 
Fridovich. The supernatant (500µl) was added to 0.800ml of carbonate buffer (100mM, pH 10.2) 
and 100µl of epinephrine (3mM). The change in absorbance of each sample was then recorded at 
480nm in spectrophotometer for 2min at an interval of 15sec. Parallel blank and standard were 
run for determination of SOD activity. 
  One unit of SOD is defined as the amount of enzyme required to produce 50% 
inhibition of epinephrine auto oxidation. 
  
Reagents 
 
Uninhibited 
(Standard) 
 
Inhibited (Sample) 
 
Blank 
 
      
 Carbonate buffer  0.900ml 0.800ml  1.0ml 
 Supernatant         -  0.1ml              -  
 Epinephrine  0.1ml 0.1ml         -  
The reaction mixtures are diluted 1/10 just before taking the readings in spectrophotometer 
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13.2 ESTIMATION OF LIPID PEROXIDASE (LPO) 119 
The  level  of  Lipid  peroxidase  was  estimated  by  Thiobarbituric  acid  reaction  
method described by Ohkawa et al. 
REAGENTS 
1. Sodium dodecyl sulphate (SDS) (8.1% w/v) 
 
2. Acetic acid (20%; pH 3.5) 
 
3. Thiobarbituric acid (TBA) (0.8%) 
 
4. n-butanol/pyridine mixture (15:1) 
 
PROCEDURE 
To 0.2ml of test sample, 0.2ml of SDS, 1.5ml of acetic acid and 1.5ml of TBA were 
added. The mixture was made up to 4ml with water and then heated in a water bath at 95°C 
for 60min. After cooling, 1ml of water and 5ml of n-butanol/pyridine mixture were added and 
shaken vigorously. After centrifugation at 4000rpm for 10min, the organic layer was taken 
and its absorbance was read at 532nm. The level of lipid peroxides was expressed as nmoles 
of MDA released/g wet tissue. 
 
Reagents Sample Blank 
SDS 
 
Supernatant 
0.2ml 
 
0.2ml 
0.2ml 
 
- 
 
DDW 
 
1.6ml 
 
1.8ml 
 
Acetic acid 
 
1.5ml 
 
1.5ml 
 
TBA 
 
1.5ml 
 
1.5ml 
 
n-butanol/pyridine 
 
5ml 
 
5ml 
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14. METHODS FOR HISTOPATHOLOGICAL STUDY  
 The mice from each group were anaesthetized using intra peritoneal injection of 
thiopentone sodium. The brain was carefully removed without any injury after opening the skull.  
liver and  kidney are also dissected carefully without any damage to the tissues. The collected 
organs were washed with ice cold normal saline and fixed in 10% buffered neutral formalin. The 
tissues were processed for routine paraffin embedding and 5 micron sections were stained with 
Mayer’s Haematoxylin Eosin stain.   
   15. STATISTICAL ANALYSIS  
 The statistical analysis was carried by one way ANOVA followed by Dunnet’s ―tǁ test. P 
values <0.05 (95% confidence limit) was considered statistically significant, using Software 
Graph pad Prism 6.0 
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16. TABLES AND GRAPHS 
 
TABLE 1: PHYTOCHEMICAL SCREENING OF VACHA CHURNAM 
 
S.NO CONSTITUENTS REMARKS 
1 Alkaloids Present 
2 Carbohydrates Present 
3 Protein Present 
4 Steroids Present 
5 Phenols Present 
6 Tannins Present 
7 Flavonoids Present 
8 Glycosides Present 
9 Saponins Present 
10 Terpenes Present 
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TABLE 2: EFFECT OF VACHA CHURNAM IN ACUTE TOXICITY STUDY 
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20 
 
 
22 
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TABLE 3:  EFFECT OF VACHA CHURNAM IN ELEVATED ZERO MAZE: 
S.NO GROUP 
% TIME 
SPENT IN 
OPEN  ARM 
% ENTRIES IN 
OPEN  ARM 
1 Control 2.50±0.86 11.25±1.90 
2 Negative Control 1.05±0.68 9.75±4.30 
3 Standard 11.17±1.58 37.7±4.72 
4 
Vacha churna 
200mg/kg 
7.12±0.63 30.8±0.68 
5 
Vacha churna 
400mg/kg 
10.61±3.65 35.35±4.46 
 
Values are represented in Mean ± SEM, n=6 
Comparison: a- Group III vs Group IV and Group V 
Statistical significance test for comparison was done by one way ANOVA followed by 
Dunnet’s ‘t’ test. 
ns- Non significant, *p<0.05, **p<0.01, ***p<0.001 
GRAPH 1:  EFFECT OF VACHA CHURNAM IN ELEVATED ZERO MAZE: 
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TABLE 4:  EFFECT OF VACHA CHURNAM IN LIGHT-DARK TEST: 
S.NO GROUP 
TIME SPENT 
IN LIT AREA 
(Sec) 
NO. OF 
TRANSITIONS 
1 Control 49.67±4.90 19.83±1.25 
2 Negative Control 30.26±3.31 17±1.28 
3 Standard 101.83±5.08 31.33±1.91 
4 
Vacha churna 
200mg/kg 
47±4.80 23.83±2.41 
5 
Vacha churna 
400mg/kg 
70.00±5.97 27.93±3.30 
 
Values are represented in Mean ± SEM, n=6 
Comparison: a- Group III vs Group IV and Group V 
Statistical significance test for comparison was done by one way ANOVA followed by 
Dunnet’s ‘t’ test. 
ns- Non significant, *p<0.05, **p<0.01, ***p<0.001 
GRAPH 2:  EFFECT OF VACHA CHURNAM IN LIGHT-DARK TEST: 
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TABLE 5:  EFFECT OF VACHA CHURNAM IN MARBLE BURYING BEHAVIOR: 
S.NO GROUP 
NO. OF MARBLES 
BURIED 
1 Control 16.75±0.57 
2 Negative Control 18.78±0.67 
3 Standard 6.25±0.63 
4 
Vacha churna 
200mg/kg 
14.25±0.47 
5 
Vacha churna 
400mg/kg 
10.25±0.25 
 
Values are represented in Mean ± SEM, n=6 
Comparison: a- Group III vs Group IV and Group V 
Statistical significance test for comparison was done by one way ANOVA followed by 
Dunnet’s ‘t’ test. 
ns- Non significant, *p<0.05, **p<0.01, ***p<0.001 
GRAPH 3:  EFFECT OF VACHA CHURNAM IN MARBLE BURYING BEHAVIOR: 
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TABLE 6:  EFFECT OF VACHA CHURNAM IN MORRIS WATER MAZE: 
S.NO GROUP 
ESCAPE 
LATENCY(SEC) 
1 Control 15.8±2.3 
2 Negative Control 59.3±7.3 
3 Standard 11.02±5.3 
4 Vacha churna 200mg/kg 16.0±2.6 
5 Vacha churna 400mg/kg 13.0±1.6 
 
Values are represented in Mean ± SEM, n=6 
Comparison: a- Group III vs Group IV and Group V 
Statistical significance test for comparison was done by one way ANOVA followed by 
Dunnet’s ‘t’ test. 
ns- Non significant, *p<0.05, **p<0.01, ***p<0.001 
GRAPH 4:  EFFECT OF VACHA CHURNAM IN MORRIS WATER MAZE: 
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TABLE 7:  EFFECT OF VACHA CHURNAM IN ACTOPHOTOMETER: 
S.NO GROUP 
LOCOMOTOR 
ACTIVITY 
1 Control 357.75±5.39 
2 Negative Control 459.75±3.49 
3 Standard 110±5.35 
4 Vacha churna 200mg/kg 259.5±7.59 
5 Vacha churna 400mg/kg 156.75±3.83 
 
Values are represented in Mean ± SEM, n=6 
Comparison: a- Group III vs Group IV and Group V 
Statistical significance test for comparison was done by one way ANOVA followed by 
Dunnet’s ‘t’ test. 
ns- Non significant, *p<0.05, **p<0.01, ***p<0.001 
GRAPH 5:  EFFECT OF VACHA CHURNAM IN ACTOPHOTOMETER: 
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TABLE 8:  EFFECT OF VACHA CHURNAM IN HOLE BOARD: 
S.NO GROUP 
NO. OF 
LINE 
CROSSING 
NO. OF 
HEAD 
DIPPING 
NO. OF 
REARING 
1 Control 66.25±2.46 22.5±1.5 10.25±0.75 
2 Negative Control 82±1.78 25.5±1.8 12.25±0.95 
3 Standard 26.5±1.55 8.7±0.5 1.75±0.75 
4 
Vacha churna 
200mg/kg 
56.5±1.19 17.75±0.94 8±0.41 
5 
Vacha churna 
400mg/kg 
41.5±3.17 12±0.40 5.25±0.48 
 
Values are represented in Mean ± SEM, n=6 
Comparison: a- Group III vs. Group IV and Group V 
Statistical significance test for comparison was done by one way ANOVA followed by 
Dunnet’s ‘t’ test. 
ns- Non significant, *p<0.05, **p<0.01, ***p<0.001 
GRAPH 6:  EFFECT OF VACHA CHURNAM IN HOLE BOARD: 
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TABLE 9:  EFFECT OF VACHA CHURNAM IN ACETYLCHOLINESTERASE (ACHE) 
S.NO GROUP 
ng/mg WET 
TISSUE 
1 Control 25.63±0.57 
2 Negative Control 12.34±0.67 
3 Standard 23.34±0.12 
4 Vacha churna 200mg/kg 15.34±0.2 
5 Vacha churna 400mg/kg 20.98±0.11 
 
Values are represented in Mean ± SEM, n=6 
Comparison: a- Group III vs Group IV and Group V 
Statistical significance test for comparison was done by one way ANOVA followed by 
Dunnet’s ‘t’ test. 
ns- Non significant, *p<0.05, **p<0.01, ***p<0.001 
GRAPH 7:  EFFECT OF VACHA CHURNAM IN ACETYLCHOLINESTERASE 
(ACHE): 
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TABLE 10:  EFFECT OF VACHA CHURNAM IN DOPAMINE 
S.NO GROUP ng/mg WET TISSUE 
1 Control 430.23±20.34 
2 Negative Control 308.45±2.45 
3 Standard 400.23±3.2 
4 Vacha churna 200mg/kg 239.47±2.55 
5 Vacha churna 400mg/kg 381.45±4.34 
 
Values are represented in Mean ± SEM, n=6 
Comparison: a- Group III vs Group IV and Group V 
Statistical significance test for comparison was done by one way ANOVA followed by 
Dunnet’s ‘t’ test. 
ns- Non significant, *p<0.05, **p<0.01, ***p<0.001 
GRAPH 8:  EFFECT OF VACHA CHURNAM IN DOPAMINE  
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TABLE 11:  EFFECT OF VACHA CHURNAM IN SEROTONIN: 
S.NO GROUP ng/mg WET TISSUE 
1 Control 243.34±5.6 
2 Negative Control 181.33±5.34 
3 Standard 235.55±5.32 
4 Vacha churna 200mg/kg 203±2.72 
5 Vacha churna 400mg/kg 225.34±2.89 
  
Values are represented in Mean ± SEM, n=6 
Comparison: a- Group III vs Group IV and Group V 
Statistical significance test for comparison was done by one way ANOVA followed by 
Dunnet’s ‘t’ test. 
ns- Non significant, *p<0.05, **p<0.01, ***p<0.001 
GRAPH 9:  EFFECT OF VACHA CHURNAM IN SEROTONIN: 
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TABLE 12:  EFFECT OF VACHA CHURNAM IN SUPEROXIDE DISMUTASE (SOD): 
S.NO GROUP 
Units/mg wet 
tissue 
1 Control 9.32±0.4 
2 Negative Control 4.1±0.25 
3 Standard 9.02±0.41 
4 Vacha churna 200mg/kg 5.99±0.3 
5 Vacha churna 400mg/kg 7.187±0.21 
 
Values are represented in Mean ± SEM, n=6 
Comparison: a- Group III vs Group IV and Group V 
Statistical significance test for comparison was done by one way ANOVA followed by 
Dunnet’s ‘t’ test. 
ns- Non significant, *p<0.05, **p<0.01, ***p<0.001 
GRAPH 10:  EFFECT OF VACHA CHURNAM IN SUPEROXIDE DISMUTASE (SOD): 
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TABLE 13:  EFFECT OF VACHA CHURNAM IN LIPID PEROXIDASE (LPO): 
S.NO GROUP Units/mg wet tissue 
1 Control 70.1±0.3 
2 Negative Control 109.3±0.23 
3 Standard 72.34±1.3 
4 Vacha churna 200mg/kg 95.45±1.23 
5 Vacha churna 400mg/kg 80.23±1.32 
 
Values are represented in Mean ± SEM, n=6 
Comparison: a- Group III vs Group IV and Group V 
Statistical significance test for comparison was done by one way ANOVA followed by 
Dunnet’s ‘t’ test. 
ns- Non significant, *p<0.05, **p<0.01, ***p<0.001 
GRAPH 11:  EFFECT OF VACHA CHURNAM IN LIPID PEROXIDASE (LPO): 
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17. RESULTS 
17.1 PRELIMINARY PHYTOCHEMICAL ANALYSIS 
The preliminary phytochemical analysis on Vacha Churnam revealed the presence of 
various phytoconstituents including alkaloids, carbohydrates, protein, steroids, phenols, tannins, 
flavonoids, etc. which are given in Table 1. 
17.2 ACUTE ORAL TOXICITY STUDIES 
The acute oral toxicity was done according to OECD 423(acute toxic class method) 
guidelines. A single administration of starting dose of 2000mg/kg of body weight p.o. of Vacha 
Churna was administered to the three female mice and observed for three days. There was no 
change in the body weight before and after treatment of the experiment and no sign of 
toxicity were observed. Observations are shown in Table 2 
17.3 IN VIVO PARAMETERS 
17.3.1 EFFECT OF VACHA CHURNAM IN ELEVATED ZERO MAZE 
The Group II animals showed decreased in percentage of alteration when compared with 
Group I animals. Treatment with Vacha Churna (200 and 400 mg/kg) showed (p<0.05 and 
p<0.01 for Groups IV and V respectively) increase time spent duration in open arm when 
compared with group II which was comparable with that of standard. Results are given in Table 
3 and plotted in Graph 1. 
17.3.2 EFFECT OF VACHA CHURNAM IN LIGHT-DARK TEST 
The Group II animals showed decrease in time spent in light compartment when 
compared with Group I animals. Treatment with Vacha Churna (200 and 400 mg/kg) showed 
(p<0.05 and p<0.01 for Groups IV and V respectively) increase time spent duration in light 
compartment  when compared with group II which was comparable with that of standard. 
Results are given in Table 4 and plotted in Graph 2. 
17.3.3 EFFECT OF VACHA CHURNAM IN MARBLE BURYING BEHAVIOR 
The Group II animals buried more no. of marbles when compared with Group I animals. 
Treatment with Vacha Churna (200 and 400 mg/kg) showed (p<0.05 and p<0.01 for Groups 
IV and V respectively) decreased burying behavior when compared with group II which was 
comparable with that of standard. Results are given in Table 5 and plotted in Graph 3. 
Study Of Anxiolytic Activity In Mice Using Vacha Churanam (Rasayana Preparation- Ayurvedic System Of Medicine) 
 
Department of Pharmacology Page 93 
 
17.3.4 EFFECT OF VACHA CHURNAM IN MORRIS WATER MAZE 
The escape latency of group II was much higher when compared with group I. 
Treatment with Vacha Churna (200 and 400 mg/kg) showed (p<0.05 and p<0.01 for Groups 
IV and V respectively) decreased escape latency on hidden platform when compared with 
group II which was comparable with that of standard. Results are given in Table 6 and plotted 
in Graph 4. 
17.3.5 EFFECT OF VACHA CHURNAM IN ACTOPHOTOMETER 
The Group II animals showed significant increase in locomoter activity when compared 
with Group I animals. Treatment with Vacha Churna (200 and 400 mg/kg) showed decrease in 
locomoter activity statistically (p<0.05 and p<0.01 for Groups IV and V respectively) and 
Group III also showed decreased activity when compared with Group II. Results are given in 
Table 7 and plotted in Graph 5. 
17.3.6 EFFECT OF VACHA CHURNAM IN HOLE BOARD 
The no. of line crossing, head dipping and rearing of group II was decreased when 
compared with group I. Treatment with Vacha Churna (200 and 400 mg/kg) showed (p<0.05 
and p<0.01 for Groups IV and V respectively) increased no. of line crossing, head dipping and 
rearing when compared with group II which was comparable with that of standard. Results are 
given in Table 8 and plotted in Graph 6. 
 17.4 NEUROTRANSMITTERS ESTIMATION 
17.4.1 EFFECT OF VACHA CHURNAM IN ACETYLCHOLINESTERASE 
The brain AchE level in group II was significantly decreased when compared with group 
I. Treatment with Vacha Churna (200 and 400 mg/kg) showed (p<0.05 and p<0.01 for Groups 
IV and V respectively) increased AchE levels in brain when compared with group II which was 
comparable with that of standard. Results are given in Table 9 and plotted in Graph 7. 
17.4.2 EFFECT OF VACHA CHURNAM IN DOPAMINE 
The brain dopamine level in group II was significantly decreased when compared with 
group I. Treatment with Vacha Churna (200 and 400 mg/kg) showed (p<0.05 and p<0.01 for 
Groups IV and V respectively) increased dopamine levels in brain when compared with group 
II which was comparable with that of standard. Results are given in Table 10 and plotted in 
Graph 8. 
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17.4.3 EFFECT OF VACHA CHURNAM IN SEROTONIN 
The brain serotonin level in group II was significantly decreased when compared with 
group I. Treatment with Vacha Churna (200 and 400 mg/kg) showed (p<0.05 and p<0.01 for 
Groups IV and V respectively) increased serotonin levels in brain when compared with group II 
which was comparable with that of standard. Results are given in Table 11 and plotted in Graph 
9. 
17.5 ESTIMATION OF ANTIOXIDANT ENZYME 
17.5.1 EFFECT OF VACHA CHURNAM IN SUPEROXIDE DISMUTASE 
The SOD levels in brain in group II was significantly decreased when compared with 
group I. Treatment with Vacha Churna (200 and 400 mg/kg) showed (p<0.05 and p<0.01 for 
Groups IV and V respectively) increased SOD levels in brain when compared with group II 
which was comparable with that of standard. Results are given in Table 12 and plotted in Graph 
10 
17.5.2 EFFECT OF VACHA CHURNAM IN LIPID PEROXIDASE 
The LPO levels in group II was significantly increased when compared with group I. 
Treatment with Vacha Churna (200 and 400 mg/kg) showed (p<0.05 and p<0.01 for Groups IV 
and V respectively) decreased LPO levels when compared with group II which was comparable 
with that of standard. Results are given in Table 13 and plotted in Graph 11. 
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17.6 ASSESSMENT OF HISTOPATHOLOGICAL CHANGES 
It was observed that there was decrease in density of neuronal cells and disrupted in the 
normal distribution of neuronal cells in Group II animals with respect to Group I animals. 
Treatment groups (Group III, IV, V) exhibited improved neuronal configuration than Group II. 
Group IV and V showed significant improvement in the density of neuronal cells of brain when 
compared with neuronal loss in negative control group (Group II). Whereas Group III showed 
improvement in the density of neuronal cells. Histopathological pictures are shown in  
          
 Fig. 5:  Control      Fig. 6: Standard  
          
        Fig. 7: Negative Control                                 Fig. 8: Low Dose  
 
                                                    
                Fig. 9: High Dose 
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18. DISCUSSION 
Benzodiazepines have been extensively used for the last 40 years to treat several forms of 
anxiety, but due to their unwanted side effects, alternative treatment strategies with favorable 
side-effect profiles, credible benefits and moderate costs are of interest, especially in primary 
care settings. 
  Medicinal plants and herbal therapy like Ayurveda, Siddha, Unani are a good source to 
find new remedies for these disorders. In the search for an alternative, more specific, and perhaps 
cost-free therapy, research has been conducted to investigate natural anxiolytic drugs.  
The effects of 200 and 400 mg/kg of Vacha churnam on the Elevated zero maze, light–
dark test, actophtometer, morris water maze, hole board etc. were almost equivalent to that of 
4mg/kg diazepam. 
In the present study, the anxiolytic activity of Vacha Churnam was observed at doses of 
200 and 400 mg/kg in mice. These observations clearly indicate that Vacha churnam exerts an 
anxiolytic activity. 
Anxiolytic activity of Vacha churnam is likely to be associated with essential constituents 
present in it reported in plant description and literature review. It is reported that vacha churnam 
exhibited anti-convulsant properties, and anxiolytic and sedative effects.  
Literature review has suggested that many clinical trials have been conducted and it was 
reported that vacha churnam exhibited many properties in CNS disorders. 
Vacha churnam is also used for the management of CNS disorders. Vacha churnam may 
be a useful in the management of neurodegenerative diseases, such as Alzheimer's disease, on 
account of its multifarious effects, that is, memory-improving property and anticholinesterase 
activity 
  In summary, Vacha churna has an anxiolytic activity. 
Study Of Anxiolytic Activity In Mice Using Vacha Churanam (Rasayana Preparation- Ayurvedic System Of Medicine) 
 
Department of Pharmacology Page 97 
 
19. CONCLUSION 
The selected dose 200mg/kg and 400mg/kg of Vacha Churnam showed significant 
action in memory and retention, cognitive, anxiolytic behavior but higher dose 400mg/kg 
showed better action than lower dose 200mg/kg.  
Literature review concluded that vacha churnam exhibited many activities in CNS 
disorders. So, I conclude that vacha churnam is effective in anxiety and anxiety related 
behavior.  
It showed potent depletion in anxiety related parameters and had very good response 
in in vitro studies such as serotonin, AchE, dopamine, SOD etc. 
Further pharmacological and chemical investigations are required to elucidate the 
exact mechanism of action of this extract and to isolate the active principles responsible for 
such effects. 
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